<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Synth Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Synth Biol</journal-id>
    <journal-id journal-id-type="publisher-id">sb</journal-id>
    <journal-id journal-id-type="coden">asbcd6</journal-id>
    <journal-title-group>
      <journal-title>ACS Synthetic Biology</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2161-5063</issn>
    <issn pub-type="epub">2161-5063</issn>
    <publisher>
      <publisher-name>American
Chemical
Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">4277759</article-id>
    <article-id pub-id-type="doi">10.1021/sb400168u</article-id>
    <article-categories>
      <subj-group>
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Forcefield_NCAA: <italic>Ab Initio</italic> Charge
Parameters to Aid in the Discovery and Design of Therapeutic Proteins
and Peptides with Unnatural Amino Acids and Their Application to Complement
Inhibitors of the Compstatin Family</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Khoury</surname>
          <given-names>George
A.</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Smadbeck</surname>
          <given-names>James</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Tamamis</surname>
          <given-names>Phanourios</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Vandris</surname>
          <given-names>Andrew C.</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <name>
          <surname>Kieslich</surname>
          <given-names>Chris A.</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath6">
        <name>
          <surname>Floudas</surname>
          <given-names>Christodoulos A.</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
      </contrib>
      <aff id="aff1">Department of Chemical and
Biological Engineering, <institution>Princeton University</institution>, Princeton, New Jersey 08544, <country>United States</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Phone: <phone>609-258-4595</phone>. Fax: <fax>609-258-0211</fax>.
E-mail: <email>floudas@titan.princeton.edu</email>.</corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>01</month>
      <year>2015</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>06</day>
      <month>01</month>
      <year>2014</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>19</day>
      <month>12</month>
      <year>2014</year>
    </pub-date>
    <volume>3</volume>
    <issue>12</issue>
    <fpage>855</fpage>
    <lpage>869</lpage>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>10</month>
        <year>2013</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2014 American Chemical
Society</copyright-statement>
      <copyright-year>2014</copyright-year>
      <copyright-holder>American Chemical
Society</copyright-holder>
      <license>
        <license-p>This is an open access article published under an ACS AuthorChoice <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0010" id="ab-tgr1"/>
      </p>
      <p>We describe the development and testing
of <italic>ab initio</italic> derived, AMBER ff03 compatible charge
parameters for a large library
of 147 noncanonical amino acids including β- and N-methylated
amino acids for use in applications such as protein structure prediction
and <italic>de novo</italic> protein design. The charge parameter
derivation was performed using the RESP fitting approach. Studies
were performed assessing the suitability of the derived charge parameters
in discriminating the activity/inactivity between 63 analogs of the
complement inhibitor Compstatin on the basis of previously published
experimental IC<sub>50</sub> data and a screening procedure involving
short simulations and binding free energy calculations. We found that
both the approximate binding affinity (<italic>K</italic>*) and the
binding free energy calculated through MM-GBSA are capable of discriminating
between active and inactive Compstatin analogs, with MM-GBSA performing
significantly better. Key interactions between the most potent Compstatin
analog that contains a noncanonical amino acid are presented and compared
to the most potent analog containing only natural amino acids and
native Compstatin. We make the derived parameters and an associated
web interface that is capable of performing modifications on proteins
using Forcefield_NCAA and outputting AMBER-ready topology and parameter
files freely available for academic use at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://selene.princeton.edu/FFNCAA">http://selene.princeton.edu/FFNCAA</uri>. The forcefield allows one to incorporate these customized amino
acids into design applications with control over size, van der Waals,
and electrostatic interactions.</p>
    </abstract>
    <kwd-group>
      <kwd>noncanonical amino
acids</kwd>
      <kwd>unnatural amino acids</kwd>
      <kwd>AMBER partial charges</kwd>
      <kwd>complement</kwd>
      <kwd>inhibitors</kwd>
      <kwd>Compstatin</kwd>
      <kwd>molecular dynamics</kwd>
    </kwd-group>
    <funding-group>
      <funding-statement>
        <funding-source>National Institutes of Health, United States</funding-source>
      </funding-statement>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>sb400168u</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>sb-2013-00168u</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <p id="sec1">A timely goal in drug discovery
is to have the ability to design new analogs that will stimulate or
inhibit a receptor involved in a particular disease process. Several
approaches spanning different molecular-weight scales exist to do
this. Namely the discovery of small molecules, peptides, peptidomimetics,
and high molecular weight antibody therapeutics are all means to create
new drugs to address a variety of disease targets. The discovery of
such molecules is challenging, with pharmaceutical companies spending
billions of dollars each year on the research, development, and optimization
of the affinity and bioavailability properties. Problems with pharmacokinetics
and bioavailability were estimated to be the cause of 40% of failures
in clinical trials,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> which is troublesome
considering the cost of getting a drug to market is approaching $1
billion.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup></p>
  <p>Protein design is increasingly
becoming a means to address some
of the challenges faced by small molecules. Over 200 peptides, proteins,
or antibodies have been marketed as of 2010,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> and it has been predicted that by 2020 we will see a larger number
of peptides as drugs.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Protein/peptide
design faces its own difficulties though. These include passively
permeating the cell membrane, being soluble at biologically relevant
concentrations and pH values, and being subjected to proteolytic cleavage,
which quickly reduces the half-life. In fact, unmodified peptides
cannot circulate in the bloodstream for longer than a few minutes
due to proteolytic cleavage,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> which hinders
any potential therapeutic application of the most specific and highest
affinity binders that are designed against a target.</p>
  <p>Synthetic
biology can potentially address several of the limitations
of traditional peptide design through the introduction of post-translational
modifications (PTMs) and unnatural amino acids. These noncanonical
amino acids (NCAAs) are chemical and biological derivatives of the
20 canonical amino acids and upon their introduction can improve both
pharmacokinetic and pharmacodynamic properties of a peptide–drug
candidate while maintaining some of the core of the side-chain scaffold
to preserve key interactions. Additionally, backbone N-methylated
and <sc>d</sc>-amino acids are a viable approach to block proteolytic
cleavage and improve metabolic stability.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> From a protein design standpoint, they offer the ability to diversify
the sequence space remarkably. A 10 amino acid peptide has a sequence
space of 20<sup>10</sup> = 1.024<italic> × </italic>10<sup>13</sup>. Considering the 20 amino acids and the over 400 PTMs that exist<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> in nature, the sequence space of that same 10-amino acid peptide
becomes 420<sup>10</sup> = 1.71<italic> × </italic>10<sup>26</sup>, and that only accounts for the <sc>l</sc>-amino acids. Thus, introduction
of modified amino acids as design choices substantially expands the
complexity of reaching the globally optimal design solution as was
pointed out in a recent review.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p>
  <p>It is not well understood how NCAAs affect protein structure. Unnatural
amino acids have been shown to have utility in rational design applications,
and thus, binding data exists of peptide analogues containing unnatural
amino acids and corresponding performance metrics including <italic>K</italic><sub>D</sub> and IC<sub>50</sub>/EC50s. Modified amino
acids can change the local electrostatic and conformational environment
of a protein and may cause a variety of downstream biological responses.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Although incorporation of NCAAs has been shown
to change the affinity and inhibitory/stimulatory potency of a peptide,
it is currently difficult to pursue rationalizations into the key
interactions contributing to that increase due to lack of forcefields
to model them.</p>
  <p>Experimentally, one can incorporate noncanonical
amino acids by
peptide synthesis,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> through bio-orthogonal
chemistry,<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> or genetically.<sup><xref ref-type="bibr" rid="ref14">14</xref>−<xref ref-type="bibr" rid="ref16">16</xref></sup> Evolution so far has been unable to address NCAA design naturally,
as the machinery to incorporate NCAAs does not exist in most organisms.
Even though most organisms have not evolved to incorporate NCAAs,
this does not imply that they are not beneficial; it means that there
are reasons for why they were not incorporated. These reasons include
the toxicity of some of the building blocks and precursors to the
noncanonical amino acid, the lack of a metabolic pathway in an organism
to create the building block, the inability of the NCAA to be incorporated
to permeate the cytoplasm,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> the lack of
a modified aminoacyl tRNA synthetase that can accept the modified
amino acid, the lack of an expanded genetic code in the organism,
or the lack of a tRNA to decode a modified genetic code. There have
been examples where each of these reasons has been successfully engineered.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> Despite organisms having limited ability to naturally incorporate
NCAAs, we have derived means to synthetically introduce them.</p>
  <p>Complicating the matter is that it is prohibitively expensive to
screen a large library of noncanonical amino acid designs. Even the
cost of incorporating a few modified amino acids is often an order
of magnitude higher than the same scaffold sequence with only natural
amino acids. The extreme cost is attributed to raw materials, synthesis,
and purification costs, which contribute their own unique difficulties
and require attention. These difficulties can be overcome with attention
to each modification’s characteristics but do not make the
screening of large libraries of modified amino acids on peptides or
proteins tractable. Nonetheless, there exist many examples where noncanonical
amino acids were experimentally incorporated into therapeutic peptides
targeting different disease and functional processes, as shown in
Table <xref rid="tbl1" ref-type="other">1</xref>. A novel approach that can computationally
screen potential analogues and has agreement with experimental data
would offer a competitive advantage to its possessor.</p>
  <p>Several
groups have created methods to design proteins and peptides
containing natural amino acids computationally that have been experimentally
validated. RosettaDesign<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> has been applied
to design a number of different peptides to bind to targets,<sup><xref ref-type="bibr" rid="ref26">26</xref>−<xref ref-type="bibr" rid="ref28">28</xref></sup> as well as design enzymes for diverse applications.<sup><xref ref-type="bibr" rid="ref29">29</xref>−<xref ref-type="bibr" rid="ref33">33</xref></sup> Citizen-scientists have applied algorithms available in the Rosetta
suite of tools to design a new enzyme for higher Diels-Alderase activity
using an online multiplayer game.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> An
iterative optimization approach has been created and applied to designing
chimeric variants of dihidrofolate reductase<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> and to switch the cofactor preference of an enzyme.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Until recently, methods for computational design only addressed
the natural amino acids. Kuhlman and co-workers<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> have recently extended the Rosetta<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> suite of tools to be able to handle several noncanonical amino acids,
constructed an extended rotamer library, and used the parameters with
Rosetta to perform design to derivatize peptides based on calpastatin
to calpain-1. Zagrovic and co-workers have created parameters<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> and tools<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> for a
library of modified amino acids compatible with the GROMACS simulation
engine.</p>
  <table-wrap id="tbl1" position="float">
    <label>Table 1</label>
    <caption>
      <title>Examples of Non-canonical Amino Acids
Incorporated into Therapeutic Peptide Agonists and Antagonists Targeting
Various Diseases</title>
    </caption>
    <table frame="hsides" rules="groups" border="0">
      <colgroup>
        <col align="left"/>
        <col align="left"/>
        <col align="left"/>
        <col align="left"/>
      </colgroup>
      <thead>
        <tr>
          <th style="border:none;" align="center">non-canonical amino acid</th>
          <th style="border:none;" align="center">therapeutic peptide</th>
          <th style="border:none;" align="center">diseases targeted</th>
          <th style="border:none;" align="center">source</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td style="border:none;" align="left">biphenylalanine 2′-et-4′-ome-biphenylalanine 2-napthylalanine</td>
          <td style="border:none;" align="left">truncated
variant of GLP1-peptide</td>
          <td style="border:none;" align="left">diabetes</td>
          <td style="border:none;" align="left">Mapelli et al.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left"><sc>d</sc>-amino acids</td>
          <td style="border:none;" align="left">Rosetta designed
peptides</td>
          <td style="border:none;" align="left">Alzheimer’s</td>
          <td style="border:none;" align="left">Sievers et
al.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">2-indanylglycine</td>
          <td style="border:none;" align="left">oxytocin variants</td>
          <td style="border:none;" align="left">inhibition of uterine motor activity</td>
          <td style="border:none;" align="left">Bakos et
al.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">2-napthylalanine</td>
          <td style="border:none;" align="left">T140 variants</td>
          <td style="border:none;" align="left">CXCR4/HIV-1</td>
          <td style="border:none;" align="left">Tamamura et al.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">O-methyltyrosine</td>
          <td style="border:none;" align="left">carbetocin</td>
          <td style="border:none;" align="left">prevention of uterine atony, induction,
and control of postpartum
bleeding or hemorrhage</td>
          <td style="border:none;" align="left">Vlieghe et al.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">O-ethyltyrosine</td>
          <td style="border:none;" align="left">atosiban</td>
          <td style="border:none;" align="left">delaying the birth in case of premature birth</td>
          <td style="border:none;" align="left">Vlieghe et al.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">1-napthylalanine</td>
          <td style="border:none;" align="left">angiotensin I variants</td>
          <td style="border:none;" align="left">hypertension</td>
          <td style="border:none;" align="left">Kokubu et al.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">1-methyltryptophan, 5-methyltryptophan</td>
          <td style="border:none;" align="left">Compstatin variants</td>
          <td rowspan="5" style="border:none;" align="left">stroke, heart attack,
Alzheimer’s, asthma,
rheumatoid arthritis, systemic lupus</td>
          <td style="border:none;" align="left">Mallik et al.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></td>
        </tr>
        <tr>
          <td style="border:none;" align="left">cyclohexylalanine</td>
          <td style="border:none;" align="left"> </td>
          <td style="border:none;" align="left"> </td>
        </tr>
        <tr>
          <td style="border:none;" align="left">phosphotyrosine</td>
          <td style="border:none;" align="left"> </td>
          <td style="border:none;" align="left"> </td>
        </tr>
        <tr>
          <td style="border:none;" align="left">aminoisobutyric acid</td>
          <td style="border:none;" align="left"> </td>
          <td style="border:none;" align="left"> </td>
        </tr>
        <tr>
          <td style="border:none;" align="left">N-methylated amino
acids</td>
          <td style="border:none;" align="left"> </td>
          <td style="border:none;" align="left">Qu et al.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup></td>
        </tr>
      </tbody>
    </table>
  </table-wrap>
  <p>The Floudas
group had notable success designing peptides with natural
amino acids that have been validated experimentally on 6 protein targets,
producing inhibitors and agonists of proteins
that are linked to different diseases.<sup><xref ref-type="bibr" rid="ref40">40</xref>−<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref53">53</xref></sup> These designs include entry inhibitors
of HIV gp41,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> agonists and antagonists
of the Complement component C3a receptor,<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> inhibitors of Complement component C3c,<sup><xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref53">53</xref></sup> and the redesign of
human β-defensin-2.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> We recently
developed Forcefield_PTM,<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> a set of AMBER
parameters for 32 frequently occurring post-translational modifications.
Here, we present new forcefield charge parameters and a web interface
to allow for the introduction of 147 noncanonical amino acids into
peptides and proteins. The optimized charge parameters are validated
on their ability to discriminate between active and inactive analogs
of Compstatin for the inhibition of complement component C3c with
approximate binding affinity and binding free energy calculations.
Subsequently, the new forcefield parameters are used to understand
the precise interactions in the most potent Compstatin analog containing
a noncanonical amino acid compared with its unmodified counterpart
and the original native sequence. Thus, with this new parameter set,
we can understand how unnatural amino acids affect binding and other
structural properties through molecular simulations.</p>
  <sec id="sec2">
    <title>Results and Discussion</title>
    <sec id="sec2.1">
      <title>New Forcefield
Charge Parameters for 147 Non-Canonical Amino
Acids</title>
      <p>Partial charges were calculated for every atom in the
library of 147 noncanonical amino acids listed in Table <xref rid="tbl2" ref-type="other">2</xref> in accordance with the ff03 methodology.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> The new parameters for each NCAA are presented in the <xref rid="notes-2" ref-type="notes">Supporting Information</xref> section “Forcefield
Parameters for Each Non-canonical Amino Acid Modification Grouped
by Scaffold Residue” and are freely available for download
and direct import into AMBER at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://selene.princeton.edu/FFNCAA">http://selene.princeton.edu/FFNCAA</uri>. Conventions for atom and three-letter code naming were done mainly
in line with corresponding CIF files contained in the PDB when contained
there so the parameters can be used directly with corresponding input
PDB files. Images of each NCAA are also provided in the <xref rid="notes-2" ref-type="notes">Supporting Information</xref> with all atoms explicitly
labeled.</p>
      <p>With the determination of these parameters, we next
present the results of our efforts to test the parameters on experimental
binding data and subsequently to understand the key interactions involved
in the most potent Compstatin analog in Table <xref rid="tbl3" ref-type="other">3</xref> containing the unnatural amino acid 1-methyltryptophan relative
to its scaffold sequence.</p>
    </sec>
    <sec id="sec2.2">
      <title>Predictive Ability of Approximate Binding
Affinity in Discriminating
Active and Inactive Analogs of Compstatin</title>
      <p>Independent molecular
dynamics simulations for all 63 Compstatin variants reported in Table <xref rid="tbl3" ref-type="other">3</xref> were carried out in complex with C3c and in isolation.
An independent simulation of the protein C3c without the peptide bound
was also carried out. The approximate binding affinity was calculated
as in eq <xref rid="eq7" ref-type="disp-formula">7</xref> (see <xref rid="sec3" ref-type="other">Methods</xref>). The analogs were rank ordered by <italic>K</italic>* from highest
to lowest. Then, an ROC curve was constructed to assess the predictive
ability of the approximate binding affinity metric to discriminate
between active and inactive analogs. Two cutoffs were chosen for defining
whether an analog was active or inactive: 20 μM and 200 μM.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Table of Modified Amino Acids for
Which Charge Parameters Are Presented in This Work Grouped by Scaffold
Amino Acid<xref rid="tbl2-fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <tbody>
            <tr>
              <td style="border:none;" align="left">
                <bold>alanine</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>phenylalanine</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>asparagine</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>aspartic
acid</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>cysteine</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">α-aminoisobutyric acid (AIB)</td>
              <td style="border:none;" align="left">(R)-α-methyl-phenylalanine
(MPH)</td>
              <td style="border:none;" align="left">N4-methyl-asparagine (MEN)</td>
              <td style="border:none;" align="left">N-methylaspartic
acid (NMD)</td>
              <td style="border:none;" align="left">(R)-<sc>l</sc>-α-methylcysteine (MCY)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">2-aminobutyric acid (ABA)</td>
              <td style="border:none;" align="left">2-ethyl-4-O-methyl-biphenylalanine
(TEF)</td>
              <td style="border:none;" align="left">(2s,4s)-2,5-diamino-4-hydroxy-5-oxopentanoic acid
(GHG)</td>
              <td style="border:none;" align="left">2-amino-propanedioic acid (FGL)</td>
              <td style="border:none;" align="left">cysteine acetamide (YCM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">adamanthane (ADA)</td>
              <td style="border:none;" align="left">3-methyl-biphenylalanine (TMB)</td>
              <td style="border:none;" align="left">glutamine hydroxamate
(HGA)</td>
              <td style="border:none;" align="left">3-methyl-aspartic acid (2AS)</td>
              <td style="border:none;" align="left">N-methylcysteine
(NMC)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">2-aminoheptanoic acid (AHP)</td>
              <td style="border:none;" align="left">3-O-methyl-biphenylalanine (TOM)</td>
              <td style="border:none;" align="left">N-methyl-asparagine
(NMN)</td>
              <td style="border:none;" align="left">2-amino-6-oxopimelic acid (26P)</td>
              <td style="border:none;" align="left">carboxymethylated cysteine (CCS)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-cyclopentylalanine
(CP3)</td>
              <td style="border:none;" align="left">2-ethyl-biphenylalanine (EBP)</td>
              <td style="border:none;" align="left">β-asparagine
(NBA)</td>
              <td style="border:none;" align="left">β-aspartic acid (DBA)</td>
              <td style="border:none;" align="left">benzylcysteine
(BCS)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">diethylalanine (DLE)</td>
              <td style="border:none;" align="left">2-methyl-4-O-methyl-biphenylalanine (MFO)</td>
              <td style="border:none;" align="left">
                <bold>tryptophan</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>glycine</bold>
              </td>
              <td style="border:none;" align="left">s-(2-hydroxyethyl)-cysteine
(OCY)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">R(+)-α-Allylalanine (AAL)</td>
              <td style="border:none;" align="left">2-methyl-biphenylalanine (MBP)</td>
              <td style="border:none;" align="left">5-methyltryptophan
(MTR)</td>
              <td style="border:none;" align="left">2-indanyl-glycine (IGL)</td>
              <td style="border:none;" align="left">s-acetonylcysteine
(CSA)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">(R)-α-ethyl alanine (REA)</td>
              <td style="border:none;" align="left">biphenylalanine (BFA)</td>
              <td style="border:none;" align="left">1-methyltryptophan (OMW)</td>
              <td style="border:none;" align="left">vinylglycine (LVG)</td>
              <td style="border:none;" align="left">β-cysteine (CBA)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">(S)-α-ethyl alanine (SEA)</td>
              <td style="border:none;" align="left">2-methylphenylalanine
(MH2)</td>
              <td style="border:none;" align="left">N-methyltryptophan (NMW)</td>
              <td style="border:none;" align="left">phenylglycine
(004)</td>
              <td style="border:none;" align="left">
                <bold>methionine</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">cyclohexylalanine (ALC)</td>
              <td style="border:none;" align="left">3-methylphenylalanine (APD)</td>
              <td style="border:none;" align="left">2-hydroxytryptophan (TRO)</td>
              <td style="border:none;" align="left">4-hydroxyphenylglycine
(D4P)</td>
              <td style="border:none;" align="left">hydroxyl-methionine (ME0)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">1-napthylalanine (ALN)</td>
              <td style="border:none;" align="left">4-methylphenylalanine (4PH)</td>
              <td style="border:none;" align="left">4-amino-tryptophan (4IN)</td>
              <td style="border:none;" align="left">(2s)-amino(3,5-dihydroxyphenyl)-ethanoic
acid (3FG)</td>
              <td style="border:none;" align="left">ethionine (ESC)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">2-napthylalanine (NAL)</td>
              <td style="border:none;" align="left">4-tert-butyl-phenylalanine (TP4)</td>
              <td style="border:none;" align="left">6-methyltryptophan (TR6)</td>
              <td style="border:none;" align="left">N-methylglycine (NMG)</td>
              <td style="border:none;" align="left">N-methyl-methionine (MME)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">5-hydroxy-1-napthalene
(NO1)</td>
              <td style="border:none;" align="left">4-amino-phenylalanine (HOX)</td>
              <td style="border:none;" align="left">5-methoxytryptophan
(MT5)</td>
              <td style="border:none;" align="left">2-allyl-glycine (2AG)</td>
              <td style="border:none;" align="left">β-methionine
(MBA)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">6-hydroxy-2-naphthalene (NO2)</td>
              <td style="border:none;" align="left">4-methoxy-phenylalanine (0A1)</td>
              <td style="border:none;" align="left">β-hydroxy-tryptophane
(HTR)</td>
              <td style="border:none;" align="left">β-glycine (GBA)</td>
              <td style="border:none;" align="left">
                <bold>leucine</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(9-anthryl)-alanine (ANT)</td>
              <td style="border:none;" align="left"><italic>m</italic>-amidinophenyl-3-alanine (APM)</td>
              <td style="border:none;" align="left">5-hydroxytryptophan
(HRP)</td>
              <td style="border:none;" align="left">
                <bold>valine</bold>
              </td>
              <td style="border:none;" align="left"><italic>t</italic>-butyl-leucine (BUG)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(2-pyridyl)-alanine
(PY2)</td>
              <td style="border:none;" align="left">4-carbamimidoyl-phenylalanine (0BN)</td>
              <td style="border:none;" align="left">β-tryptophan (WBA)</td>
              <td style="border:none;" align="left">(R)-(+)-α-methylvaline
(MVL)</td>
              <td style="border:none;" align="left">norleucine (NLE)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(3-pyridyl)-alanine
(PY3)</td>
              <td style="border:none;" align="left">4-hydroxymethyl-phenylalanine (4HP)</td>
              <td style="border:none;" align="left">
                <bold>tyrosine</bold>
              </td>
              <td style="border:none;" align="left">norvaline (NVA)</td>
              <td style="border:none;" align="left">5-oxo-norleucine (ONL)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(4-pyridyl)-alanine
(PY4)</td>
              <td style="border:none;" align="left">3-ethyl-phenylalanine (DMP)</td>
              <td style="border:none;" align="left">O-methyltyrosine
(OMY)</td>
              <td style="border:none;" align="left">N-methyl-valine (MVA)</td>
              <td style="border:none;" align="left">N-methyl-leucine
(MLE)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(2-quinolyl)-alanine (Q32)</td>
              <td style="border:none;" align="left">3,4-dimethylphenylalanine (D34)</td>
              <td style="border:none;" align="left">O-ethyltyrosine
(OEY)</td>
              <td style="border:none;" align="left">β-valine (VBA)</td>
              <td style="border:none;" align="left">homoleucine
(HLE)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(3-quinolyl)-alanine (Q33)</td>
              <td style="border:none;" align="left">phenylserine (BB8)</td>
              <td style="border:none;" align="left">O-allyltyrosine (OAY)</td>
              <td style="border:none;" align="left">
                <bold>threonine</bold>
              </td>
              <td style="border:none;" align="left">(R)-α-methylleucine
(RML)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(4-quinolyl)-alanine (Q34)</td>
              <td style="border:none;" align="left">homophenylalanine (HPE)</td>
              <td style="border:none;" align="left">N-methyltyrosine (NMY)</td>
              <td style="border:none;" align="left">N-methylthreonine (NMT)</td>
              <td style="border:none;" align="left">β-hydroxyleucine
(HLU)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(5-quinolyl)-alanine (Q35)</td>
              <td style="border:none;" align="left">3,3-diphenylalanine (DIF)</td>
              <td style="border:none;" align="left">O-tyrosine (OTY)</td>
              <td style="border:none;" align="left"><italic>o</italic>-methyl-threonine (OLT)</td>
              <td style="border:none;" align="left">hydroxynorvaline
(VAH)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(6-quinolyl)-alanine (Q36)</td>
              <td style="border:none;" align="left">kynurenine (KYN)</td>
              <td style="border:none;" align="left">3-amino-tyrosine (TY2)</td>
              <td style="border:none;" align="left">β-threonine (TBA)</td>
              <td style="border:none;" align="left">β-leucine (LBA)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-(8-hydroxyquinolin-3-yl)-alanine (HQA)</td>
              <td style="border:none;" align="left">N-methyl-phenylalanine (MEA)</td>
              <td style="border:none;" align="left">3-amino-6-hydroxy-tyrosine (TYQ)</td>
              <td style="border:none;" align="left">
                <bold>lysine</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>serine</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-methylalanine
(NMA)</td>
              <td style="border:none;" align="left">β-phenylalanine (FBA)</td>
              <td style="border:none;" align="left">(β-R)-β-hydroxy-tyrosine
(OMX)</td>
              <td style="border:none;" align="left">(R)-α-methylornithine (RMO)</td>
              <td style="border:none;" align="left">homoserine (HSE)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">1-pyrenylalanine (PAL)</td>
              <td style="border:none;" align="left">
                <bold>isoleucine</bold>
              </td>
              <td style="border:none;" align="left">β-tyrosine (YBA)</td>
              <td style="border:none;" align="left">(S)-α-methylornithine (SMO)</td>
              <td style="border:none;" align="left">2-amino-5-hydroxypentanoic acid (LDO)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">(R)-2-(2′-propenyl)-alanine (PRP)</td>
              <td style="border:none;" align="left">N-methylisoleucine (NMI)</td>
              <td style="border:none;" align="left">
                <bold>glutamic acid</bold>
              </td>
              <td style="border:none;" align="left">2,3-diaminopropanoic acid (DPP)</td>
              <td style="border:none;" align="left">6-hydroxy-norleucine (AA4)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">(R)-2-(4′-pentenyl)-alanine (PEN)</td>
              <td style="border:none;" align="left">allo-isoleucine
(IIL)</td>
              <td style="border:none;" align="left">N-methylglutamic acid (NME)</td>
              <td style="border:none;" align="left">diaminobutyric
acid (DAB)</td>
              <td style="border:none;" align="left">N-methyl-serine (NMS)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">(R)-2-(7′-octenyl)-alanine (OCT)</td>
              <td style="border:none;" align="left">3-methyl-alloisoleucine
(I2M)</td>
              <td style="border:none;" align="left">(3r)-3-methyl-glutamic acid (LME)</td>
              <td style="border:none;" align="left">(2s)-2,8-diaminooctanoic acid (HHK)</td>
              <td style="border:none;" align="left">β-serine
(SBA)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">β-alanine (AAB)</td>
              <td style="border:none;" align="left">β-isoleucine (IBA)</td>
              <td style="border:none;" align="left">(3s)-3-methyl-glutamic acid
(MEG)</td>
              <td style="border:none;" align="left">N-methyl-lysine (NMK)</td>
              <td style="border:none;" align="left">
                <bold>histidine</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>glutamine</bold>
              </td>
              <td style="border:none;" align="left">
                <bold>arginine</bold>
              </td>
              <td style="border:none;" align="left">2s,4r-4-methylglutamate (SYM)</td>
              <td style="border:none;" align="left">β-lysine (KBA)</td>
              <td style="border:none;" align="left">N-methylhistidine (NMH)</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-methylglutamine (NMQ)</td>
              <td style="border:none;" align="left">N-methylarginine
(NMR)</td>
              <td style="border:none;" align="left">5-<italic>o</italic>-methyl-glutamic acid (GME)</td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N5-methyl-glutamine
(MEQ)</td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">3-methyl glutamine (LMQ)</td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">β-glutamine
(QBA)</td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
              <td style="border:none;" align="left"> </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tbl2-fn1">
            <label>a</label>
            <p>Corresponding three-letter codes
are listed in parentheses following each amino acid.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Parts A and B of Figure <xref rid="fig1" ref-type="fig">1</xref> present the results
of the predictive ability of this metric for this system using the
forcefield parameters derived. The approximate binding affinity metric
can reasonably discriminate between active and inactive analogs with
areas under the ROC curve of 0.691 and 0.721 corresponding to a cutoff
for active analogs with IC<sub>50</sub> &lt; 20 μM and &lt;200
μM, respectively. Only 1 false positive was observed in the
top 10 ranked analogs by <italic>K</italic>*, and 6 false positives
by the 20 μM IC<sub>50</sub> cutoff were observed in the top
20. This result is encouraging, since <italic>K</italic>* has previously
been used as the final discriminating metric in our <italic>de novo</italic> protein design framework<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> using only natural amino acids. This suggests that <italic>K</italic>* can be used to reasonably discriminate between active/inactive
analogs for new designs of Compstatin with the AMBER energy function
and molecular dynamics simulations.</p>
    </sec>
    <sec id="sec2.3">
      <title>Predictive Ability of Binding
Free Energy Calculations in Discriminating
Active and Inactive Analogs of Compstatin</title>
      <p>An independent
molecular dynamics simulation of the complex with each of the 63 variants
of Compstatin and C3c was carried out. Snapshots from the simulations
were used to perform MM-GBSA calculations to evaluate the binding
free energies of each analog. Parts C and D of Figure <xref rid="fig1" ref-type="fig">1</xref> present the results of the ability for MM-GBSA to discriminate
between active and inactive analogs. Binding free energy calculations
performed using the forcefield parameters and MM-GBSA yielded the
greatest discriminatory ability with areas under the ROC curve of
0.808 and 0.936 corresponding to a cutoff for active analogs with
IC<sub>50</sub> &lt; 20 μM and &lt;200 μM, respectively.
This suggests that using the forcefield parameters with MM-GBSA can
accurately discriminate between active and inactive analogs of Compstatin.
In fact, in the top 10 sequences’ calculated Δ<italic>G</italic><sub>Bind,Solv</sub><sup arrange="stack">°GBSA</sup>, there was only 1 false positive for either of the
IC<sub>50</sub> cutoffs (in the seventh position), and 6 false positives
in the top 20 sequences. Removing the sequences corresponding to deletions
of Compstatin in order to compare only equal sequence-length analogs
yields an area under the curve of 0.702 and 0.869 for a cutoff IC<sub>50</sub> of &lt;20 μM and &lt;200 μM, respectively.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Receiver
operating characteristic (ROC) curves constructed from
rank-ordered lists of Compstatin variants’ binding metrics.
ROC curve for rank ordered list by <italic>K</italic>* corresponding
to an active IC<sub>50</sub> cutoff of &lt;20 μM (A) and 200
μM (B). ROC curve for rank ordered list by Δ<italic>G</italic><sub>Bind,Solv</sub><sup arrange="stack">°GBSA</sup> to an active IC<sub>50</sub> cutoff of &lt;20 M (C) and 200 μM
(D).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0003" id="gr1" position="float"/>
      </fig>
      <p>We next asked whether there exists
a correlation observed between
experimental IC<sub>50</sub> and calculated binding free energy as
IC<sub>50</sub> values were found to be strongly correlated (<italic>R</italic><sup>2</sup> = 0.887) with <italic>K</italic><sub>D</sub> values in the work of Magotti and co-workers.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> IC<sub>50</sub> data was used over <italic>K</italic><sub>D</sub> due to the much larger number of experimental data points
available for this system, important for achieving statistical significance
in the results. Ideally, a larger number of <italic>K</italic><sub>D</sub> values would be available to perform similar assessments.
We observed a weak correlation between IC<sub>50</sub> and binding
free energy in Figure <xref rid="fig2" ref-type="fig">2</xref>. The existence of a
correlation is in agreement with data presented by Magotti.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup></p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Correlation between IC<sub>50</sub> and calculated binding
free
energies using MM-GBSA for 63 Compstatin analogs. The blue bands correspond
to the 95% confidence interval for the regression line. The red bands
correspond to the 95% confidence interval for a new value to lie in
the prediction band. Error bars are ±1 standard deviation from
the mean binding free energy calculated.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0004" id="gr2" position="float"/>
      </fig>
      <p>It is interesting that the binding free energy metric performed
better than the approximate binding affinity (<italic>K</italic>*),
since the approximate binding affinity of each analog compared to
the template sequence has been used as the final discriminator of
which analogs to send for experimental testing in our <italic>de novo</italic> design framework,<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> and has been successfully
applied to designing inhibitors of HIV entry<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> and inhibitors of Complement activation<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> previously. This suggests that we should use the calculated binding
free energy if possible instead of the approximate binding affinity
when designing new Compstatin variants. Despite these results, the
approximate binding affinity calculation will still be useful to assess
the docking of complexes when the binding mode is unknown. Additional
testing with different sets of protein/peptide complexes beyond C3c/Compstatin
should be evaluated in the future to provide further evidence supporting
the use of these binding evaluation metrics. Similarly, future testing
with different systems having more experimental <italic>K</italic><sub>D</sub> data can be performed.</p>
    </sec>
    <sec id="sec2.4">
      <title>Discriminating Differences
in Interactions in Compstatin Analogs
with Natural and Modified Amino Acids</title>
      <p>Due to the new forcefield
parameters derived in this work, we have the capability to discriminate
interfacial interactions involving noncanonical amino acids at atomistic
detail. The most potent analog of Compstatin in Table <xref rid="tbl3" ref-type="other">3</xref> contains the noncanonical amino acid 1-methyltryptophan in
position 4. We aimed to gain insight as to why this substitution is
more potent than the analog W4A9 and native Compstatin based on strengths
of residue–residue interactions. Therefore, for multiple independent
simulation trajectories of analogs W4(OMW)A9, W4A9, and native Compstatin
(Sequence 11: Ac-ICV(OMW)QDWGAHRCT-NH2, Sequence 23: Ac-ICVWQDWGAHRCT-NH2,
and Sequence 53: ICVVQDWGHHRCT in Table <xref rid="tbl3" ref-type="other">3</xref>),
we decomposed the polar and nonpolar interaction free energy contributions
and present the results of the average interaction free energies as
two-dimensional density maps in Figure <xref rid="fig3" ref-type="fig">3</xref>. Here,
we focus on differences in interactions due to 1-methyltryptophan
relative to tryptophan or valine present in other Compstatin sequences.
A full detailed analysis of all pairwise interactions is presented
in <xref rid="notes-2" ref-type="notes">Supporting Information</xref> section “Use
of FF_NCAA to Discriminate Specific Contributing Interactions to Antagonistic
Activity for Unnaturally Modified Analog Compared to Native and Variant
E1 Compstatin.”</p>
      <p>The substitutions of Val4 to Trp4 and
from Trp4 to W4(OMW) result in an increase of the overall nonpolar
interactions between residue 4 and C3c residues Gly345, Met346, Asn390,
Thr391, His392, Pro393, and Arg456; the increase is more pronounced
in the 390–393 C3c residue moiety, as was previously proposed
through molecular modeling by Magotti and co-workers.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> During the simulations of analog W4(OMW)A9, the methyl
group of Trp4 is frequently found to lay upon the Cys2-Cys12 disulfide
bridge, and this leads to increased intramolecular nonpolar interactions
between Trp4 and Cys2-Cys12. Similar behavior was observed in recently
published MD computational studies<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> investigating
two novel analogs, R1W4(OMW)A9 and R-1S0W4(OMW)A9, which also contain
1-methyltryptophan in position 4 and using the CHARMM forcefield.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> W4(OMW) forms increased intra- and intermolecular
interactions compared with the less potent analogs containing Trp4
and Val4. In all systems, the backbone N in Val/Trp4 is hydrogen bonded
to C3c Gly345 O, and the backbone O in Val/Trp4 is hydrogen bonded
to the charged amide group of C3c Arg456; the former hydrogen bond-related
polar interaction is stronger in the parent Compstatin, whereas the
latter is stronger in W4(OMW)A9. The full set of intermolecular interactions
formed between the Compstatin analogs and C3c residues in Figure <xref rid="fig3" ref-type="fig">3</xref> are in agreement with the X-ray structure of W4A9
in complex with C3c<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> and with all previous
MD simulation studies in explicit water solvent<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> using the CHARMM forcefield. Despite the
specific differences between the analogs, overall, the strengths of
the residue pairwise interaction free energies of the three systems
were similar.</p>
    </sec>
    <sec id="sec2.5">
      <title>FF_NCAA Web Interface</title>
      <p>To disseminate
the ability to
use FF_NCAA to the broader academic community, we have also created
a web interface <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://selene.princeton.edu/FFNCAA">http://selene.princeton.edu/FFNCAA</uri>, as
shown in Figure <xref rid="fig4" ref-type="fig">4</xref>. The interface allows one
to upload a PDB structure to be modified by single or multiple noncanonical
amino acids and/or simultaneously mutated. Additionally, the interface
allows a user to download the forcefield parameters calculated and
derived for FF_NCAA, as well as read instructions for use with AMBER
directly.</p>
      <p>After user submission, the interface performs the
requested modifications and minimizes the structure to remove any
clashes that have been formed by introducing the noncanonical amino
acid to the nearest local minimum. This step utilizes the parameters
from FF_NCAA for the noncanonical amino acids coupled with the parameters
in ff03.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> After completion, the user will
receive an e-mail indicating the structure’s successful modification
with a unique link to download their results. The user can visualize
the modified and input structure using a Jmol applet integrated into
the web interface. Additionally, the interface provides links to relevant
information tabulated about the structures including the TMScore and<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> and RMSD between the structures, and the molecular-mechanics
calculated energy of the structure. In addition, the topology and
parameter files are generated for AMBER and are provided so that one
can directly use them as input for further molecular dynamics simulation
on the user’s local computing systems. Disulfide bridges in
the input structure are automatically detected and introduced by the
web interface. The web interface will be useful to researchers aiming
to interactively make site-specific noncanonical amino acid substitutions
on a protein structure/complex and to perform subsequent binding calculations
in AMBER locally.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>(A) Nonpolar and (B) polar interaction maps for analog
W4(OMW)A9.
(C) Nonpolar and (D) polar interaction maps for analog W4A9. (E) Nonpolar
and (F) polar interaction maps for native Compstatin. The color bar
represents the interaction free energy between the corresponding residue–residue
pairs in kcal/mol. The color bar was scaled to be the same for the
nonpolar and polar interaction free energy contributions so that the
different analogues’ energetic contributions can be directly
compared.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0005" id="gr3" position="float"/>
      </fig>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Web interface for the dissemination of Forcefield_NCAA.
The web
interface has static links to download and use Forcefield_NCAA in
AMBER locally, as well as an interactive interface to make noncanonical
amino acid substitutions and mutations to an input PDB structure.
Screenshot taken April 25, 2013.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0006" id="gr4" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="methods" id="sec3">
    <title>Methods</title>
    <sec id="sec3.1">
      <title>Procedure for Calculation and Derivation
of Forcefield Parameters
in Forcefield_NCAA</title>
      <p>Quantum calculations to derive partial
charges compatible with AMBER ff03 were performed consistent with
the procedure of Duan and co-workers<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> for
the 20 natural amino acids. The ff03 methodology was chosen due to
the noncanonical amino acids having multiple R-groups attached to
the <italic>C</italic><sub>α</sub> or substitutions such as
methylation on the backbone nitrogen. Therefore, the consensus fixed-backbone
charges in other AMBER fixed-charge forcefields would not be applicable.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The choices for NCAAs chosen to be parametrized
were based on those found in the literature to enhance the binding
affinity of a peptide to a receptor protein, α,α-disubstituted
modified amino acids, N-methylated amino acids, and β-amino
acids. The procedure used is shown in Figure <xref rid="fig5" ref-type="fig">5</xref> and is adapted from the procedure we developed to derive parameters
in Forcefield_PTM<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> for parametrizing frequently
occurring post-translational modifications.</p>
      <p>In the first step,
structures of each unnatural amino acid dipeptide were built using
the MarvinSketch program.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> Dipeptides
are constructed to mimic the peptide backbone with a core amino acid
with a preceding and subsequent amino acid. An acetyl group precedes
the amino acid to be parametrized, with an N-methyl group following
it in the form ACE-X-NME, where X is the amino acid to be parametrized. <sc>l</sc>-Amino acids were constructed, unless otherwise noted by designations
of (R) or (S) for the disubstituted amino acids. In the second step,
the distance geometry (<bold>distgeom</bold>) module in TINKER 5.1<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> is used to construct α-helix (ϕ
= −60, ψ = −40) and β-strand (ϕ =
−120, ψ = −140) conformers. In Step 3, through
TINKER, utilizing the AMBER ff94<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> parameter
set, and using restraints on the main-chain torsion angles, each conformer
was subjected to 25 simulated annealing calculations (using the <bold>anneal</bold> routine with default parameters). <italic>T</italic><sub>i</sub> and <italic>T</italic><sub>f</sub> were 1000 K and 0
K in the annealing. 2000 steps of cooling are done in each simulation,
employing a linear cooling protocol and a 1 fs time step. This procedure
was performed to find suitable feasible points for subsequent detailed
optimization at the quantum mechanical level. For both the helix and
strand conformer, the lowest energy structure for each was minimized
to the nearest local minima using the <bold>optimize</bold> routine,
with a RMS gradient cutoff of 0.01. <italic>Gaussian09</italic>(<xref ref-type="bibr" rid="ref62">62</xref>) was used to optimize (Step 5) each conformer
at the HF/6-31G** level of theory, with restraints on the ϕ
and ψ angles to preserve the backbone secondary structure. Single
point energy calculations are next performed on the dipeptide structures
using the density functional theory method and the B3LYP exchange
and correlation functionals<sup><xref ref-type="bibr" rid="ref63">63</xref>−<xref ref-type="bibr" rid="ref65">65</xref></sup> and the cc-pVTZ<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> basis set. An ether-like organic solvent environment (ε
= 4) was mimicked by applying the IEFPCM implicit solvent model,<sup><xref ref-type="bibr" rid="ref67">67</xref>,<xref ref-type="bibr" rid="ref68">68</xref></sup> as suggested by Duan.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> The electrostatic
potential (ESP) was calculated at a set of gridpoints defining the
molecular surface in the solvent-accessible region around each optimized
conformation at 1.4, 1.6, 1.8, and 2.0 times the vdw radii using the
program DMS at a density of 0.5, yielding 2.5–2.8 points/Å<sup>2</sup>.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> The ESP values calculated from
each conformation were next used as input to a two-stage RESP fit
of the partial atomic charges using Antechamber in AmberTools 1.4.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> In the RESP model, atoms are reasonably approximated
as spherical points having fixed charges rather than as nuclei with
shared electrons. Bond, angle, and dihedral force constants were perceived
by matching atom types contained in the General Amber Forcefield (GAFF)<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> using Antechamber.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> GAFF torsion parameters, when applied to post-translational modifications,
were shown previously to be highly correlated with and reproduce the
locations of local maxima/minima on the quantum mechanically calculated
potential energy surface of key torsion angles, although their amplitudes
needed refinement.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> Subsequent refinement
of key bonded parameters may be warranted but are not developed in
this work due to the extreme computational cost involved and since
the parameters developed herein are intended to be used mainly in
a design context. This procedure was completed for a total of 147
diverse noncanonical amino acids spanning all amino acids except Proline.
No new atom types were needed in the matching of force constants and
equilibrium values. Further, in 99 of the 147 molecules parametrized,
no parameters were utilized from GAFF since AMBER already had defined
the parameters for all of the atom types for those noncanonical amino
acids. The method described is similar to that described by Khoury
et al.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> with the changes being able to
handle α,α-disubstituted and backbone modified amino acids.
The parameters for noncanonical amino acids were next tested using
binding calculations.</p>
      <fig id="fig5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Automated framework for AMBER partial charge parametrization
for
noncanonical, α,α-disubstituted, β- and N-methylated
amino acids. Adapted with permission from ref (<xref ref-type="bibr" rid="ref50">50</xref>). Copyright 2013, American
Chemical Society.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0007" id="gr5" position="float"/>
      </fig>
    </sec>
    <sec id="sec3.2">
      <title>Testing the Parameters
Using Approximate Binding Affinity and
Binding Free Energy Calculations of 63 Compstatin Analogs</title>
      <sec id="sec3.2.1">
        <title>Selection
of System for Testing and Extraction of Data from
the Literature</title>
        <p>We aimed to create charge parameters for noncanonical
amino acids that would be compatible with the existing AMBER ff03
forcefield parameters for natural amino acids. We focused on assessing
whether the derived parameters can discriminate between active/inactive
analogs of an inhibitor, since we expect the charge parameters derived
to be used mainly in a protein design context. This approach is viable
since there are sets of binding data available in the literature where
others have experimentally incorporated noncanonical amino acids for
various therapeutic applications.</p>
        <p>The availability of (i) an
experimentally solved structure for Compstatin variant E1 (the ligand)
bound to human Complement component C3c<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> (the receptor) and (ii) an abundance of experimental binding and
IC<sub>50</sub> data available, and the observation that (iii) the
ligand peptide is relatively rigid because of a disulfide bond that
cyclizes it which limits the entropic contribution to the binding
free energy, led us to focus our testing efforts on the Complement/Compstatin
system. There are three pathways in the Complement system: the classical
pathway, the lectin pathway, and the alternative pathway.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> All three pathways converge on a single step
where the key protein, C3 binds to C3 convertase and causes it to
become cleaved into C3a and C3b (which contains C3c), which allows
downstream events to occur leading to the membrane attack complex
that can cleave cells. Compstatin binds to C3 and the C3 convertase,
which blocks them from coming together and becoming cleaved.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> Inhibiting their ability to bind together and
cleave inhibits the activation of C3 and disrupts the formation of
the membrane attack complex downstream. This is important as its improper
activation has been linked to over 10 autoimmune, inflammation, and
neurological disorders.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref74">74</xref>−<xref ref-type="bibr" rid="ref77">77</xref></sup></p>
        <p>Figure <xref rid="fig6" ref-type="fig">6</xref> shows a schematic diagram
of Complement
component C3c with the coordinates of the ligand peptide Compstatin
variant E1 (Ac-ICVWQDWGAHRCT-NH2) bound. Since the region that Compstatin
binds to C3c is confined and localized in one site, utilizing the
entire C3c:Compstatin complex is not necessary. In addition, because
of unresolved/missing residues in the crystal structure, and because
of its large size (643 amino acids in the solved PDB structure), using
the full structure of C3c only serves to complicate subsequent calculation
complexities, extend simulation times, and potentially add unnecessary
noise.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> Therefore,
residues F335 (macroglobulin domain 4,MG4) to D535 (MG5) were extracted
from PDB: 2QKI and used in all subsequent calculations. Previous simulations to
study this complex have shown that using these regions were sufficient
for modeling the binding interface.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup></p>
        <p>All
experimental binding data (IC<sub>50</sub>’s) on Compstatin
variants were tabulated from Magotti et al.,<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Chiu et al.,<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> and Qu et al.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> These data sets are denoted by structurekinetic,
pharmacophore, and novel analogues, respectively, and are shown in
Table <xref rid="tbl3" ref-type="other">3</xref>. The data set included 47 analogues
with IC<sub>50</sub> &lt; 200 μM, and 16 analogs with IC<sub>50</sub> &gt; 200 μM, as well as 31 analogues with IC<sub>50</sub> &lt; 20 μM and 32 analogs with IC<sub>50</sub> &gt; 20 μM.
In terms of diversity, the data set included 23 noncanonical amino
acid modifications, of which 11 were backbone N-methylations, 28 were
natural amino acid substitutions, and 12 were deletions. There was
no training done specific to this system in the derivation of the
parameters for the NCAAs used. All subsequent results are based only
on physical interactions derived from the physics governing the AMBER
forcefield.</p>
        <fig id="fig6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>(A) Crystal structure of Compstatin Variant E1 bound to Complement
component C3c (PDB: 2QKI). Each macroglobulin domain (MG) is denoted by color. (B) The region
where modified amino acids are to be substituted in is shown in the
inset. This is the interface that is being designed when making natural
or noncanonical amino acid substitutions. A disulfide bridge cyclizes
Compstatin between residues 2 and 12. (C) This is the full region
all calculations will be performed on, beginning with F335 from MG4
to D535 on MG5 as labeled. The images are visualized in PyMOL.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0008" id="gr6" position="float"/>
        </fig>
      </sec>
      <sec id="sec3.2.2">
        <title>Screening Compstatin Analogs with Short Molecular Dynamics Simulations
and Binding Calculations</title>
        <p>The starting coordinates of variant
E1 of Compstatin bound to Complement component C3c were taken from
PDB: 2QKI. Each
variant was constructed using the program <bold>tleap</bold> by stripping
off the side-chains and substituting them with the new amino acid,
natural or modified. Deletions were constructed by deleting the amino
acids on the peptide chain. During the initial minimization the atoms
moved to adjust for the deletions. The cysteine residues in the Compstatin
variants were connected to form disulfide bridges in all simulations
using the <bold>bond</bold> command in <bold>tleap</bold>. Acetyl
and N-methyl blocking groups were added if they were present in the
experimental analog.</p>
        <p>The molecular dynamics and screening procedure
used was done identically for each variant with AMBER11.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> Partial charges compatible with AMBER ff03<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> derived in this work were used for all noncanonical
amino acids. All simulations were performed with the generalized Born
implicit solvent model of Onufriev<sup><xref ref-type="bibr" rid="ref81">81</xref>,<xref ref-type="bibr" rid="ref82">82</xref></sup> with a 16
Å nonbonded interaction cutoff. The surface energy term was activated
and a salt concentration of 0.1 mol/L was used to account for charge
screening. Structures were minimized with 600 steps of steepest descent
followed by 400 steps of conjugate gradient minimization. The structures
were next heated by rescaling the velocities in 6 stages with increments
of 50 K from 0 K to 300 K over 30 ps and a 0.5 fs time step to heat
the structures. The collision frequency γ was 5 ps<sup>–1</sup>. Shake constraints were used to constrain all bonds between heavy
atoms and hydrogens and reduce the number of degrees of freedom. Next,
each C3c/Compstatin variant underwent a short 0.5 ns production simulation
using a 1 fs time step at 300 K. Short (&lt;1 ns) MD simulations with
the ff03 charge model have previously been shown to give better performance
in ranking binding energies than longer simulations<sup><xref ref-type="bibr" rid="ref83">83</xref></sup> and gave the best overall ranking results in an assessment
of 5 AMBER forcefields (ff99, ff99SB, ff99SB-ILDN, ff03, and ff12SB)
and 46 small molecules targeting 5 protein receptors.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup> No restraints were employed in any step of any simulation
to strictly assess the suitability of the parameters to discriminate
between active/inactive analogs of Compstatin.</p>
        <table-wrap id="tbl3" position="float">
          <label>Table 3</label>
          <caption>
            <title>Data Set Used for Testing the Optimized
Charges Introduced in Forcefield_NCAA<xref rid="tbl3-fn1" ref-type="table-fn">a</xref></title>
          </caption>
          <table frame="hsides" rules="groups" border="0">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="char" char="."/>
            </colgroup>
            <thead>
              <tr>
                <th style="border:none;" align="center">analog</th>
                <th style="border:none;" align="center">source</th>
                <th style="border:none;" align="center">sequence</th>
                <th style="border:none;" align="center">SeqID</th>
                <th style="border:none;" align="center" char=".">IC<sub>50</sub> (μM)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td style="border:none;" align="left">1</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICV(PTR)QDWGAHRCI-NH2</td>
                <td style="border:none;" align="left">28</td>
                <td style="border:none;" align="char" char=".">9.60</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">2</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-RCVVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">17</td>
                <td style="border:none;" align="char" char=".">8.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">3</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-LCVVQDWGWHRCG-NH2</td>
                <td style="border:none;" align="left">15</td>
                <td style="border:none;" align="char" char=".">5.40</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">4</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVWQDWGWHRCT-NH2</td>
                <td style="border:none;" align="left">24</td>
                <td style="border:none;" align="char" char=".">3.10</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">5</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVNDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">3</td>
                <td style="border:none;" align="char" char=".">4.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">6</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICV(OMY)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">5</td>
                <td style="border:none;" align="char" char=".">1.30</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">7</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-MCVHQDWGGHRCF-NH2</td>
                <td style="border:none;" align="left">16</td>
                <td style="border:none;" align="char" char=".">85.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">8</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVWQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">2</td>
                <td style="border:none;" align="char" char=".">2.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">9</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICV(MTR)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">3</td>
                <td style="border:none;" align="char" char=".">0.87</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">10</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAHRC(NMT)-NH2</td>
                <td style="border:none;" align="left">12</td>
                <td style="border:none;" align="char" char=".">1.90</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">11</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICV(OMW)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">1</td>
                <td style="border:none;" align="char" char=".">0.21</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">12</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVSQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">20</td>
                <td style="border:none;" align="char" char=".">50.90</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">13</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVQDWGHHSCT-NH2</td>
                <td style="border:none;" align="left">10</td>
                <td style="border:none;" align="char" char=".">25.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">14</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVQDWGHHRCI-NH2</td>
                <td style="border:none;" align="left">13</td>
                <td style="border:none;" align="char" char=".">3.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">15</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICVWQDWG(AIB)HRCT-NH2</td>
                <td style="border:none;" align="left">12</td>
                <td style="border:none;" align="char" char=".">1.50</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">16</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVWQDWGAHRCT</td>
                <td style="border:none;" align="left">25</td>
                <td style="border:none;" align="char" char=".">2.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">17</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVNDWGHHACT-NH2</td>
                <td style="border:none;" align="left">11</td>
                <td style="border:none;" align="char" char=".">60.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">18</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAHR(NMC)T-NH2</td>
                <td style="border:none;" align="left">11</td>
                <td style="border:none;" align="char" char=".">154.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">19</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICV(PAL)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">9</td>
                <td style="border:none;" align="char" char=".">1.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">20</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICV(ALC)QDWGAHRCT</td>
                <td style="border:none;" align="left">27</td>
                <td style="border:none;" align="char" char=".">53.60</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">21</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVHQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">21</td>
                <td style="border:none;" align="char" char=".">10.50</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">22</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVQDWGAHACT-NH2</td>
                <td style="border:none;" align="left">12</td>
                <td style="border:none;" align="char" char=".">9.90</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">23</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICVWQDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">0</td>
                <td style="border:none;" align="char" char=".">1.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">24</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVWQD(OMW)GAHRCT-NH2</td>
                <td style="border:none;" align="left">4</td>
                <td style="border:none;" align="char" char=".">1000.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">25</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICLVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">8</td>
                <td style="border:none;" align="char" char=".">10.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">26</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">23</td>
                <td style="border:none;" align="char" char=".">3.80</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">27</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">4</td>
                <td style="border:none;" align="char" char=".">2.40</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">28</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVWQDWG(AIB)HRCT-NH2</td>
                <td style="border:none;" align="left">29</td>
                <td style="border:none;" align="char" char=".">1.50</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">29</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICVVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">15</td>
                <td style="border:none;" align="char" char=".">4.50</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">30</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVAQDWGAHRCI-NH2</td>
                <td style="border:none;" align="left">7</td>
                <td style="border:none;" align="char" char=".">12.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">31</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICLVNDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">9</td>
                <td style="border:none;" align="char" char=".">8.30</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">32</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQD(NMW)GAHRCT-NH2</td>
                <td style="border:none;" align="left">6</td>
                <td style="border:none;" align="char" char=".">25.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">33</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICV(ALN)QDWGAHRCT</td>
                <td style="border:none;" align="left">31</td>
                <td style="border:none;" align="char" char=".">1.80</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">34</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVTQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">19</td>
                <td style="border:none;" align="char" char=".">68.30</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">35</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQ(NMD)WGAHRCT-NH2</td>
                <td style="border:none;" align="left">5</td>
                <td style="border:none;" align="char" char=".">44.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">36</td>
                <td style="border:none;" align="left">novel
analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDW(NMG)AHRCT-NH2</td>
                <td style="border:none;" align="left">7</td>
                <td style="border:none;" align="char" char=".">584.47</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">37</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVY(NMQ)DWGAHRCT-NH2</td>
                <td style="border:none;" align="left">4</td>
                <td style="border:none;" align="char" char=".">33.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">38</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">0</td>
                <td style="border:none;" align="char" char=".">2.40</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">39</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-LCVWQDWGRHQCF-NH2</td>
                <td style="border:none;" align="left">14</td>
                <td style="border:none;" align="char" char=".">131.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">40</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVFQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">22</td>
                <td style="border:none;" align="char" char=".">10.20</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">41</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGAH(NMR)CT-NH2</td>
                <td style="border:none;" align="left">10</td>
                <td style="border:none;" align="char" char=".">32.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">42</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWGA(NMH)RCT-NH2</td>
                <td style="border:none;" align="left">9</td>
                <td style="border:none;" align="char" char=".">94.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">43</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICV(OMW)QDWGPHRCT-NH2</td>
                <td style="border:none;" align="left">14</td>
                <td style="border:none;" align="char" char=".">0.54</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">44</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-DCVVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">18</td>
                <td style="border:none;" align="char" char=".">22.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">45</td>
                <td style="border:none;" align="left">structurekinetic</td>
                <td style="border:none;" align="left">Ac-ICV(OEY)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">6</td>
                <td style="border:none;" align="char" char=".">1.30</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">46</td>
                <td style="border:none;" align="left">novel
analogues</td>
                <td style="border:none;" align="left">Ac-ICVYQDWG(NMA)HRCT-NH2</td>
                <td style="border:none;" align="left">8</td>
                <td style="border:none;" align="char" char=".">1000.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">47</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVVQDWGHHRC-NH2</td>
                <td style="border:none;" align="left">del1</td>
                <td style="border:none;" align="char" char=".">33.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">48</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVVQDWGHC-NH2</td>
                <td style="border:none;" align="left">del9</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">49</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac–I(NMC)VYQDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">1</td>
                <td style="border:none;" align="char" char=".">7.50</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">50</td>
                <td style="border:none;" align="left">novel analogues</td>
                <td style="border:none;" align="left">Ac-ICV(NMY)QDWGAHRCT-NH2</td>
                <td style="border:none;" align="left">3</td>
                <td style="border:none;" align="char" char=".">1000.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">51</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">Ac-ICVVGDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">6</td>
                <td style="border:none;" align="char" char=".">567.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">52</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">del0</td>
                <td style="border:none;" align="char" char=".">25.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">53</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">ICVVQDWGHHRCT</td>
                <td style="border:none;" align="left">0</td>
                <td style="border:none;" align="char" char=".">12.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">54</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">IAVVQDWGHHRAT</td>
                <td style="border:none;" align="left">5 (Linear)</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">55</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVVQDWC-NH2</td>
                <td style="border:none;" align="left">del8</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">56</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CAVQDWGHHRC</td>
                <td style="border:none;" align="left">del10</td>
                <td style="border:none;" align="char" char=".">1200.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">57</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CWGHHRCT-NH2</td>
                <td style="border:none;" align="left">del4</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">58</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVVQDWAHHRC</td>
                <td style="border:none;" align="left">del11</td>
                <td style="border:none;" align="char" char=".">1200.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">59</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CVQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">del7</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">60</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CQDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">del6</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">61</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CDWGHHRCT-NH2</td>
                <td style="border:none;" align="left">del5</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">62</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CHHRCT-NH2</td>
                <td style="border:none;" align="left">del2</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
              <tr>
                <td style="border:none;" align="left">63</td>
                <td style="border:none;" align="left">pharmacophore</td>
                <td style="border:none;" align="left">CGHHRCT-NH2</td>
                <td style="border:none;" align="left">del3</td>
                <td style="border:none;" align="char" char=".">600.00</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tbl3-fn1">
              <label>a</label>
              <p>The noncanonical amino acids
studied are phosphotyrosine (PTR), O-methyltyrosine (OMY), N-methylthreonine
(NMT), 5-methyltryptophan (MTR), 1-methyltryptophan (OMW), α-aminoisobutyric
acid (AIB), N-methylcysteine (NMC), 1-pyrenylalanine (PAL), cyclohexylalanine
(ALC), N-methyltryptophan (NMW), 1-naphthylalanine (ALN), N-methylaspartic
acid (NMD), N-methylglycine (NMG), N-methylglutamine (NMQ), N-methyl-arginine
(NMR), N-methylhistidine (NMH), O-ethyltyrosine (OMY), N-methylalanine
(NMA), N-methyltyrosine (NMY). Several of these non-canonical amino
acids were substituted in different positions on the Compstatin sequence.
ACE and NH2 correspond to the N-terminal and C-terminal blocking groups
acetyl and amide to keep the termini neutrally charged.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <sec id="sec3.2.2.1">
          <title>Approximate Binding Affinity Calculations</title>
          <p>Three independent
simulations as described above were performed for the complex, the
protein, and the peptide, respectively. One simulation of the protein
was utilized to assess the contributions of the protein and to remove
any variability from its contribution. Sixty three independent simulations
of each complex and 63 independent simulations of each peptide were
performed in isolation using the procedure described above. The derivation
of the Approximate Binding Affinity (<italic>K</italic>*) from statistical
mechanics is described in the following.</p>
          <p>The equilibrium of
complex formation PL from a protein P and ligand L is defined as<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m001" position="anchor"/><label>1</label></disp-formula>Assuming a dilute mixture, one can assume
ideal behavior. The Helmholtz free energy <italic>A</italic> can be
related to the total partition function, <italic>Q</italic> in eq <xref rid="eq2" ref-type="disp-formula">2</xref>. <italic>Q</italic> is in turn a function of the
individual partition functions <italic>q</italic><sub><italic>i</italic></sub>, where <italic>i</italic> is PL, P, L. This assumes independence
of subsystems and that the particles are indistinguishable.<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m002" position="anchor"/><label>2</label></disp-formula>The chemical
potential μ of species <italic>i</italic> is the partial derivative
of the Helmholtz Free Energy <italic>A</italic> with respect to <italic>N</italic><sub><italic>i</italic></sub>, denoted in eq <xref rid="eq3" ref-type="disp-formula">3</xref>.<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m003" position="anchor"/><label>3</label></disp-formula>Equality of chemical
potentials at equilibrium
is denoted in eq <xref rid="eq4" ref-type="disp-formula">4</xref>.<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m004" position="anchor"/><label>4</label></disp-formula>Next, substituting eq <xref rid="eq3" ref-type="disp-formula">3</xref> into eq <xref rid="eq4" ref-type="disp-formula">4</xref> and rearranging yields.<disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m005" position="anchor"/><label>5</label></disp-formula><italic>q</italic><sub><italic>i</italic></sub> is a product of the translational (<italic>q</italic><sub>t</sub>), rotational (<italic>q</italic><sub>r</sub>), and vibrational (<italic>q</italic><sub>v</sub>) partition functions. Since <italic>q</italic><sub>t</sub> is only a function of the coordinates <italic>x</italic>, <italic>y</italic>, and <italic>z</italic>, it integrates out to
a volume <italic>V</italic>, leaving <italic>q</italic><sub><italic>i</italic></sub> = <italic>V</italic> * <italic>q</italic><sub><italic>i</italic></sub><sup arrange="stack">′</sup>(<italic>T</italic>). <italic>q</italic><sub><italic>i</italic></sub><sup arrange="stack">′</sup>(<italic>T</italic>) is the rotational and vibrational partition functions, which is
what is approximated by evaluation of <italic>E</italic><sub>intra</sub> during the snapshots sampled over the course of a molecular dynamics
trajectory. This is shown in eq <xref rid="eq6" ref-type="disp-formula">6</xref>.<disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m006" position="anchor"/><label>6</label></disp-formula>Next, the volume term can be taken out of
each partition function and therefore the ratio of the partition functions
equals the ratio of concentrations (since <italic>N</italic><sub><italic>i</italic></sub>/<italic>V</italic><sub><italic>i</italic></sub> is
a concentration). <italic>K</italic>* = <italic>K</italic><sub>A</sub> when the intrapartition functions (<italic>q</italic><sub>r</sub> and <italic>q</italic><sub>v</sub>) are exactly calculated.<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m007" position="anchor"/><label>7</label></disp-formula>Currently, it is not possible to compute exact
partition functions for a complex molecular species due to the inability
to integrate an exact energy function over the molecule’s entire
conformational space.<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> Therefore, we approximate
the partition functions as the sampled space of a molecular dynamics
trajectory scored with the AMBER potential energy function.</p>
          <p>This derivation is based on an initial derivation by Lilien et
al.<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> using rotamerically based ensembles
with modifications resulting from a personal communication between
Dr. Meghan Bellows Peterson and Professor Pablo G. Debenedetti. Using
the ratios of the partition function of the complex, peptide, and
protein, the Approximate Binding Affinity, <italic>K</italic>* was
calculated and placed in a rank ordered list from highest to lowest,
which would correspond to the largest to smallest predicted association
affinity. The Jacobi logarithm was used to handle numerical overflows
that can be caused by summing exponential terms.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup></p>
        </sec>
        <sec id="sec3.2.2.2">
          <title>Binding Free Energy Calculations</title>
          <p>Binding free energies
were calculated using the states produced over the time course of
each of the 63 molecular dynamics simulations of the complex. These
were calculated to test the forcefield parameters and also to compare
its predictive ability to the <italic>K</italic>*. In the approximate
binding affinity, independent simulations of the peptide, protein,
and complex are performed. In the binding free energy calculation,
only one simulation of the complex is required. The binding free energy
is calculated as in eq <xref rid="eq8" ref-type="disp-formula">8</xref>, utilizing the thermodynamic
cycle denoted in Figure <xref rid="fig7" ref-type="fig">7</xref>.<disp-formula id="eq8"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m008" position="anchor"/><label>8</label></disp-formula>Tamamis
et al., using the CHARMM<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> suite of tools,
showed MM-GBSA was able to show
the difference in binding Compstatin in complex with human versus
rat C3c<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> and mouse C3c.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Tamamis et al. further showed MM-GBSA was helpful in discriminating
potential analogs for experimental testing.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> Based on these previous findings, it is clear that MM-GBSA can be
used to study the Compstatin/C3c system. Therefore, in this study,
binding free energies were calculated using the MM-GBSA module<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> in AMBER11 complemented by the charge parameters
for the noncanonical amino acids introduced in this work.</p>
          <fig id="fig7" position="float">
            <label>Figure 7</label>
            <caption>
              <p>Thermodynamic
cycle used to calculate the binding free energies.
Ideally one can calculate the binding free energy for the association
of [A] + [B] ⇌ [AB] directly in solvent. This calculation is
expensive and contains much noise due to the contribution of the solvent.
Therefore, a different approach was used exploiting a thermodynamic
cycle that can calculate the same difference by utilizing the solvation
free energies of the protein (receptor), peptide (ligand), and complex,
with the binding energy calculated <italic>in vacuo</italic>.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup></p>
            </caption>
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0009" id="gr7" position="float"/>
          </fig>
          <p>For this system, we assume that the entropic contribution
due to
the binding free energy is small since the ligand’s structure
is relatively rigid due to the disulfide bridges (the maximum <italic>C</italic><sub>α</sub> RMSD between analogs W4(OMW)A9, W4A9,
and native Compstatin was 1.38 at the end of the simulation). The
entropic contribution, which can be calculated through a normal-mode
analysis, can have a large uncertainty.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> Given that we expect the Compstatin analogs to have similar entropies
due to their cyclic nature and being bound to the same binding pocket
of C3c, and because of the expected large error, the entropic contribution
in the calculation was ignored. This “one-trajectory”
approximation where we assume similar structure in the bound and unbound
state is reasonable and has been applied elsewhere<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref53">53</xref></sup> and also has been compared to the results of a “three-trajectory”
approximation for this system.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> Using
the “one-trajectory” approximation, all of the bonded
terms (bonds, angles, torsions) cancel out in the evaluation of the
binding free energies, leaving only nonbonded terms, of which the
electrostatic component is a significant contributor.</p>
        </sec>
      </sec>
      <sec id="sec3.2.3">
        <title>Construction
of Receiver Operating Characteristic Curves</title>
        <p>After the approximate
binding affinity and binding free energies
were calculated for each variant of Compstatin following the procedure
described above, the values were rank ordered from most favorable
to least favorable. For <italic>K</italic>*, this was largest to smallest,
and for Δ<italic>G</italic><sub>Bind,Solv</sub><sup arrange="stack">°</sup>, this was smallest to largest.
Receiver operating characteristic (ROC) curves were constructed based
on the rank-ordered lists of the analogs. Two cutoff values of IC<sub>50</sub> values defining active and inactive were chosen. The first
cutoff was 20 M, which corresponded to an even split between active
and inactive in the data set. That is, analogs with IC<sub>50</sub> values &lt; 20 μM were considered active. Similarly, a cutoff
of 200 μM was chosen to perform the analysis with a less stringent
cutoff of active/inactive. These values as cutoffs were determined
based on the fact that the most active Compstatin analog in Table <xref rid="tbl3" ref-type="other">3</xref> is Ac-ICV(OMW)QDWGAHRCT-NH2,<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> which has an IC<sub>50</sub> of 0.21 μM. The axes
on the ROC curve correspoμnd to the True Positive Rate (Sensitivity)
vs the False Positive Rate (1-Specificity). The ROC curve constructed
aimed to find how many of the most favorable analogs by calculated
approximate binding affinity or binding free energy were experimentally
active when rank-ordered. In a virtual screen, this is often one of
the first steps in design: to assess whether a particular ligand will
bind to its target favorably, and ranking the affinity of a ligand
to the targeted receptor. Sensitivity and specificity are defined
as.<disp-formula id="eq9"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m009" position="anchor"/><label>9</label></disp-formula>where TP, FP, TN, and FN stand for
true/false
positives/negatives, respectively.</p>
      </sec>
    </sec>
    <sec id="sec3.3">
      <title>Additional Simulations
for Analysis of Interaction Free Energies
of Compstatin Derivatives and C3 Residue Pairs</title>
      <p>Three biologically
relevant complexes containing derivatives of Compstatin (Sequence
11: Ac-ICV(OMW)QDWGAHRCT-NH2, Sequence 23: Ac-ICVWQDWGAHRCT-NH2, and
Sequence 53: ICVVQDWGHHRCT in Table <xref rid="tbl3" ref-type="other">3</xref>) were
assessed for their interactions through multiple longer-time molecular
dynamics simulations. Four independent trajectories were performed
for each complex. Each of the four trajectories for each complex were
appended together for subsequent analysis. The starting complex structures
were constructed and minimized as described previously deriving from
PDB: 2QKI. The
complexes were heated stepwise from 0 to 300K over 30 ps using restraints
on all backbone atoms with a force constant of 10 kcal/(mol·Å<sup>2</sup>). The complexes were carefully equilibrated in 3 stages;
each stage was run for 200 ps. In the first stage, all atoms were
restrained with a force constant of 5.0 kcal/(mol·Å<sup>2</sup>) for 200 ps. In the second stage, all backbone atoms outside
of the binding pocket were constrained (residues 335–343, 350–387,
394–453, 463–487, 493–535), and all atoms in
the binding pocket were constrained with a force constant of 5.0 kcal/(mol·Å<sup>2</sup>). In the final stage, all backbone atoms outside of the binding
pocket were constrained and all atoms in the binding pocket were constrained
with a force constant of 1.5 kcal/(mol·Å<sup>2</sup>). After
equilibration, four independent 10 ns production simulations were
performed for each complex. These simulations were used to produce
maps of residue–residue polar and nonpolar interaction free
energies to identify key energetic interactions important for binding
through the simulation trajectories.</p>
      <p>The interaction free energies
between two residues (<italic>R</italic> and <italic>R</italic>′)
were computed by the relation:<disp-formula id="eq10"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_0002" id="GRAPHIC-d508e3221-autogenerated" position="float"/><label>10</label></disp-formula>for each of the 3 Compstatin
variants evaluated.
The first and second group of terms on the right-hand side of eq <xref rid="eq10" ref-type="disp-formula">10</xref> describe polar and nonpolar interactions between <italic>R</italic> and <italic>R</italic>′. In the calculations, <italic>R</italic> corresponds to a residue on Compstatin and <italic>R</italic>′ corresponds to a residue on C3c. The details of the calculation
have been presented previously.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref53">53</xref>,<xref ref-type="bibr" rid="ref56">56</xref>,<xref ref-type="bibr" rid="ref57">57</xref></sup> For each complex, 4000 frames
over the 40 ns total simulation time were evaluated for their average
interaction free energies using a spacing of 10 ps per frame.</p>
    </sec>
  </sec>
</body>
<back>
  <notes id="notes-2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>(1) Table containing the raw
calculated binding affinities of different Compstatin variants. (2)
Instructions for importing new parameters into AMBER. (3) Explanation
of the contents of the forcefield parameter file. (4) Images and atom
namings of each parametrized noncanonical amino acid grouped by scaffold
residue. (5) Forcefield parameters for each noncanonical amino acid
grouped by scaffold residue. (6) The full pairwise residue–residue
analysis of interaction energy contributions for 3 important analogs
of Compstatin. (7) Zip file containing the Forcefield parameters in
AMBER formats directly importable into AMBER. This material is available
free of charge via the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb400168u_si_001.pdf">
        <caption>
          <p>sb400168u_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb400168u_si_002.zip">
        <caption>
          <p>sb400168u_si_002.zip</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes id="notes-1">
    <title>Author Contributions</title>
    <p>G.A.K. and
C.A.F. conceived the project. G.A.K. and J.S. contributed to the source
code enabling the calculation of the parameters. G.A.K. and A.V. calculated
and compiled the partial charges. J.S., C.A.K., G.A.K. contributed
to the construction of the ROC curves. G.A.K. performed the simulations
and constructed the ROC curves. G.A.K., J.S., C.A.K., and C.A.F. analyzed
the ROC curves. P.T. and G.A.K. constructed the interaction maps and
analyzed the simulation results. G.A.K. created the web interface.
G.A.K., P.T., and C.A.F. wrote the manuscript. All authors have read
and approved the manuscript.</p>
  </notes>
  <notes id="notes-3" notes-type="conflict-of-interest">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>C.A.F. acknowledges
support from the National Institutes of
Health (R01GM052032) and the National Science Foundation. G.A.K. is
grateful for support by a National Science Foundation Graduate Research
Fellowship under grant No. DGE-1148900. The authors gratefully acknowledge
that the calculations reported in this paper were performed at the
TIGRESS high performance computing center at Princeton University
which is supported by the Princeton Institute for Computational Science
and Engineering (PICSciE) and the Princeton University Office of Information
Technology. The authors are grateful to Eric First for expert help
with making the webtool. We are grateful to Dr. Meghan Bellows Peterson
and Professor Pablo G. Debenedetti for helpful discussions.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>μM</term>
        <def>
          <p>micromolar concentration</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <inline-formula>
            <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m010.gif"/>
          </inline-formula>
        </term>
        <def>
          <p>all degrees of freedom</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <inline-formula>
            <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sb-2013-00168u_m011.gif"/>
          </inline-formula>
        </term>
        <def>
          <p>all the degrees of freedom
minus the translational degrees of freedom</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>E</italic>
          <sub>intra</sub>
        </term>
        <def>
          <p>the
intramolecular energy of a system interacting with itself</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>Q</italic>
        </term>
        <def>
          <p>the total
partition function</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>q</italic>
          <sub>
            <italic>i</italic>
          </sub>
          <sup arrange="stack">′</sup>
        </term>
        <def>
          <p>the partition function over the internal
degrees of freedom</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>B</italic>
        </term>
        <def>
          <p>the set of bound configurations</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>F</italic>
        </term>
        <def>
          <p>the set of free protein
configurations</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>L</italic>
        </term>
        <def>
          <p>the set of free ligand peptide configurations</p>
        </def>
      </def-item>
      <def-item>
        <term><italic>K</italic>*</term>
        <def>
          <p>the approximate
binding affinity</p>
        </def>
      </def-item>
      <def-item>
        <term>
          <italic>K</italic>
          <sub>A</sub>
        </term>
        <def>
          <p>the binding equilibrium constant for the
association reaction P + L ⇌ PL</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name> (<year>2011</year>) <article-title>Recent advances
on aqueous solubility prediction</article-title>. <source>Comb. Chem.
High Throughput Screening</source>
<volume>14</volume>, <fpage>328</fpage>–<lpage>338</lpage>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Andrade</surname><given-names>C. H.</given-names></name>; <name><surname>Pasqualoto</surname><given-names>K. F. M.</given-names></name>; <name><surname>Ferreira</surname><given-names>E. I.</given-names></name>; <name><surname>Hopfinger</surname><given-names>A. J.</given-names></name> (<year>2009</year>) <article-title>Rational
design and 3D-pharmacophore mapping of 5′-thiourea-substituted
α-thymidine analogues as mycobacterial TMPK inhibitors</article-title>. <source>J. Chem. Inf. Model.</source>
<volume>49</volume>, <fpage>1070</fpage>–<lpage>1078</lpage>.<pub-id pub-id-type="pmid">19296716</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Vlieghe</surname><given-names>P.</given-names></name>; <name><surname>Lisowski</surname><given-names>V.</given-names></name>; <name><surname>Martinez</surname><given-names>J.</given-names></name>; <name><surname>Khrestchatisky</surname><given-names>M.</given-names></name> (<year>2010</year>) <article-title>Synthetic
therapeutic peptides: Science and market</article-title>. <source>Drug
Discovery Today</source>
<volume>15</volume>, <fpage>40</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">19879957</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Craik</surname><given-names>D. J.</given-names></name>; <name><surname>Fairlie</surname><given-names>D. P.</given-names></name>; <name><surname>Liras</surname><given-names>S.</given-names></name>; <name><surname>Price</surname><given-names>D.</given-names></name> (<year>2013</year>) <article-title>The future of peptide-based
drugs</article-title>. <source>Chem. Biol. Drug Des.</source>
<volume>81</volume>, <fpage>136</fpage>–<lpage>147</lpage>.<pub-id pub-id-type="pmid">23253135</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Adessi</surname><given-names>C.</given-names></name>; <name><surname>Soto</surname><given-names>C.</given-names></name> (<year>2002</year>) <article-title>Converting a peptide into a drug:
Strategies to improve stability
and bioavailability</article-title>. <source>Curr. Med. Chem.</source>
<volume>9</volume>, <fpage>963</fpage>–<lpage>978</lpage>.<pub-id pub-id-type="pmid">11966456</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Miller</surname><given-names>S. M.</given-names></name>; <name><surname>Simon</surname><given-names>R. J.</given-names></name>; <name><surname>Ng</surname><given-names>S.</given-names></name>; <name><surname>Zuckermann</surname><given-names>R. N.</given-names></name>; <name><surname>Kerr</surname><given-names>J. M.</given-names></name>; <name><surname>Moos</surname><given-names>W. H.</given-names></name> (<year>1995</year>) <article-title>Comparison of the
proteolytic susceptibilities
of homologous <sc>l</sc>-amino acid, <sc>d</sc>-amino acid, and N-substituted
glycine peptide and peptoid oligomers</article-title>. <source>Drug
Dev. Res.</source>
<volume>35</volume>, <fpage>20</fpage>–<lpage>32</lpage>.</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Khoury</surname><given-names>G. A.</given-names></name>; <name><surname>Baliban</surname><given-names>R. C.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2011</year>) <article-title>Proteome-wide
post-translational
modification statistics: Frequency analysis and curation of the SWISS-PROT
database</article-title>. <source>Sci. Rep.</source>
<volume>1</volume>, <fpage>1</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">22355520</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Bairoch</surname><given-names>A.</given-names></name>; <name><surname>Apweiler</surname><given-names>R.</given-names></name> (<year>2000</year>) <article-title>The SWISS-PROT protein sequence database and its supplement
TrEMBL in 2000</article-title>. <source>Nucleic Acids Res.</source>
<volume>28</volume>, <fpage>45</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">10592178</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Khoury</surname><given-names>G. A.</given-names></name>; <name><surname>Smadbeck</surname><given-names>J.</given-names></name>; <name><surname>Kieslich</surname><given-names>C. A.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2013</year>) <article-title>Protein folding
and <italic>de novo</italic> protein design for biotechnological applications</article-title>. <source>Trends Biotechnol.</source>
<pub-id pub-id-type="doi">10.1016/j.tibtech.2013.10.008</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="book" id="cit10"><person-group person-group-type="allauthors"><name><surname>Walsh</surname><given-names>C. T.</given-names></name></person-group> (<year>2006</year>) <source>Posttranslational Modification of Proteins:
Expanding Nature’s
Inventory</source>; <publisher-name>Roberts and Co. Publishers</publisher-name>, <publisher-loc>Englewood, CO</publisher-loc>, pp <fpage>xxi</fpage>, <lpage>490</lpage>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Merrifield</surname><given-names>R. B.</given-names></name> (<year>1963</year>) <article-title>Solid phase
peptide synthesis. I. The synthesis of a tetrapeptide</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>85</volume>, <fpage>2149</fpage>–<lpage>2154</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Chalker</surname><given-names>J. M.</given-names></name>; <name><surname>Davis</surname><given-names>B. G.</given-names></name> (<year>2010</year>) <article-title>Chemical mutagenesis: selective post-expression interconversion
of protein amino acid residues</article-title>. <source>Curr. Opin.
Chem. Biol.</source>
<volume>14</volume>, <fpage>781</fpage>–<lpage>789</lpage>.<pub-id pub-id-type="pmid">21075673</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Chalker</surname><given-names>J.
M.</given-names></name>; <name><surname>Bernardes</surname><given-names>G. J. L.</given-names></name>; <name><surname>Davis</surname><given-names>B. G.</given-names></name> (<year>2011</year>) <article-title>A ″tag-and-modify″
approach to site-selective protein modification</article-title>. <source>Acc. Chem. Res.</source>
<volume>44</volume>, <fpage>730</fpage>–<lpage>741</lpage>.<pub-id pub-id-type="pmid">21563755</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Johnson</surname><given-names>J. A.</given-names></name>; <name><surname>Lu</surname><given-names>Y. Y.</given-names></name>; <name><surname>Van Deventer</surname><given-names>J. A.</given-names></name>; <name><surname>Tirrell</surname><given-names>D. A.</given-names></name> (<year>2010</year>) <article-title>Residue-specific
incorporation of non-canonical amino acids into proteins: Recent developments
and applications</article-title>. <source>Curr. Opin. Chem. Biol.</source>
<volume>14</volume>, <fpage>774</fpage>–<lpage>780</lpage>.<pub-id pub-id-type="pmid">21071259</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Neumann</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>K.</given-names></name>; <name><surname>Davis</surname><given-names>L.</given-names></name>; <name><surname>Garcia-Alai</surname><given-names>M.</given-names></name>; <name><surname>Chin</surname><given-names>J. W.</given-names></name> (<year>2010</year>) <article-title>Encoding multiple unnatural amino
acids via evolution
of a quadruplet-decoding ribosome</article-title>. <source>Nature</source>
<volume>464</volume>, <fpage>441</fpage>–<lpage>444</lpage>.<pub-id pub-id-type="pmid">20154731</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Xie</surname><given-names>J.</given-names></name>; <name><surname>Schultz</surname><given-names>P. G.</given-names></name> (<year>2006</year>) <article-title>Expanding
the genetic code</article-title>. <source>Annu.
Rev. Biophys. Biomol. Struct.</source>
<volume>35</volume>, <fpage>225</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">16689635</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Watanabe</surname><given-names>T.</given-names></name>; <name><surname>Muranaka</surname><given-names>N.</given-names></name>; <name><surname>Hohsaka</surname><given-names>T.</given-names></name> (<year>2008</year>) <article-title>Four-base codon-mediated saturation
mutagenesis in a cell-free translation system</article-title>. <source>J. Biosci. Bioeng.</source>
<volume>105</volume>, <fpage>211</fpage>–<lpage>215</lpage>.<pub-id pub-id-type="pmid">18397770</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Mapelli</surname><given-names>C.</given-names></name>; et al. (<year>2009</year>) <article-title>Eleven amino acid glucagon-like peptide-1 receptor agonists with
antidiabetic activity</article-title>. <source>J. Med. Chem.</source><volume>52</volume>, <fpage>7788</fpage>–<lpage>7799</lpage>.<pub-id pub-id-type="pmid">19702274</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Sievers</surname><given-names>S. A.</given-names></name>; <name><surname>Karanicolas</surname><given-names>J.</given-names></name>; <name><surname>Chang</surname><given-names>H. W.</given-names></name>; <name><surname>Zhao</surname><given-names>A.</given-names></name>; <name><surname>Jiang</surname><given-names>L.</given-names></name>; <name><surname>Zirafi</surname><given-names>O.</given-names></name>; <name><surname>Stevens</surname><given-names>J. T.</given-names></name>; <name><surname>Munch</surname><given-names>J.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name>; <name><surname>Eisenberg</surname><given-names>D.</given-names></name> (<year>2011</year>) <article-title>Structure-based
design of non-natural amino-acid inhibitors
of amyloid fibril formation</article-title>. <source>Nature</source>
<volume>475</volume>, <fpage>96</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">21677644</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Bakos</surname><given-names>K.</given-names></name>; <name><surname>Havass</surname><given-names>J.</given-names></name>; <name><surname>Fülöp</surname><given-names>F.</given-names></name>; <name><surname>Gera</surname><given-names>L.</given-names></name>; <name><surname>Stewart</surname><given-names>J. M.</given-names></name>; <name><surname>Falkay</surname><given-names>G.</given-names></name>; <name><surname>Tóth</surname><given-names>G. K.</given-names></name> (<year>2001</year>) <article-title>Synthesis
and receptor binding of
oxytocin analogs containing conformationally restricted amino acids</article-title>. <source>Lett. Pept. Sci.</source>
<volume>8</volume>, <fpage>35</fpage>–<lpage>40</lpage>.</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Tamamura</surname><given-names>H.</given-names></name>; <name><surname>Hiramatsu</surname><given-names>K.</given-names></name>; <name><surname>Kusano</surname><given-names>a. S.</given-names></name>; <name><surname>Terakubo</surname><given-names>S.</given-names></name>; <name><surname>Yamamoto</surname><given-names>N.</given-names></name>; <name><surname>Trent</surname><given-names>J. O.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Peiper</surname><given-names>S. C.</given-names></name>; <name><surname>Nakashima</surname><given-names>H.</given-names></name>; <name><surname>Otaka</surname><given-names>A.</given-names></name>; <name><surname>Fujii</surname><given-names>N.</given-names></name> (<year>2003</year>) <article-title>Synthesis of potent CXCR4 inhibitors
possessing low cytotoxicity and improved biostability based on T140
derivatives</article-title>. <source>Org. Biomol. Chem.</source>
<volume>1</volume>, <fpage>3656</fpage>–<lpage>3662</lpage>.<pub-id pub-id-type="pmid">14649896</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Kokubu</surname><given-names>T.</given-names></name>; <name><surname>Hiwada</surname><given-names>K.</given-names></name>; <name><surname>Murakami</surname><given-names>E.</given-names></name>; <name><surname>Imamura</surname><given-names>Y.</given-names></name>; <name><surname>Matsueda</surname><given-names>R.</given-names></name>; <name><surname>Yabe</surname><given-names>Y.</given-names></name>; <name><surname>Koike</surname><given-names>H.</given-names></name>; <name><surname>Iijima</surname><given-names>Y.</given-names></name> (<year>1985</year>) <article-title>Highly potent and specific
inhibitors of human renin</article-title>. <source>Hypertension</source>
<volume>7</volume>, <fpage>I8</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">2987128</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Mallik</surname><given-names>B.</given-names></name>; <name><surname>Katragadda</surname><given-names>M.</given-names></name>; <name><surname>Spruce</surname><given-names>L. A.</given-names></name>; <name><surname>Carafides</surname><given-names>C.</given-names></name>; <name><surname>Tsokos</surname><given-names>C. G.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2005</year>) <article-title>Design and NMR characterization
of active analogues of compstatin containing non-natural amino acids</article-title>. <source>J. Med. Chem.</source>
<volume>48</volume>, <fpage>274</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">15634022</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Qu</surname><given-names>H.</given-names></name>; <name><surname>Magotti</surname><given-names>P.</given-names></name>; <name><surname>Ricklin</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>E. L.</given-names></name>; <name><surname>Kourtzelis</surname><given-names>I.</given-names></name>; <name><surname>Wu</surname><given-names>Y.-Q.</given-names></name>; <name><surname>Kaznessis</surname><given-names>Y. N.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2011</year>) <article-title>Novel analogues
of the therapeutic complement inhibitor compstatin with significantly
improved affinity and potency</article-title>. <source>Mol. Immunol.</source>
<volume>48</volume>, <fpage>481</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">21067811</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Leaver-Fay</surname><given-names>A.</given-names></name>; et al. (<year>2011</year>) <article-title>Rosetta3 an object-oriented
software suite for the simulation and
design of macromolecules</article-title>. <source>Methods Enzymol.</source><volume>487</volume>, <fpage>545</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">21187238</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Correia</surname><given-names>B. E.</given-names></name>; et al. (<year>2010</year>) <article-title>Computational design
of epitope-scaffolds allows induction of antibodies
specific for a poorly immunogenic HIV vaccine epitope</article-title>. <source>Structure</source><volume>18</volume>, <fpage>1116</fpage>–<lpage>1126</lpage>.<pub-id pub-id-type="pmid">20826338</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Fleishman</surname><given-names>S. J.</given-names></name>; <name><surname>Whitehead</surname><given-names>T. A.</given-names></name>; <name><surname>Ekiert</surname><given-names>D. C.</given-names></name>; <name><surname>Dreyfus</surname><given-names>C.</given-names></name>; <name><surname>Corn</surname><given-names>J. E.</given-names></name>; <name><surname>Strauch</surname><given-names>E.-M.</given-names></name>; <name><surname>Wilson</surname><given-names>I. A.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2011</year>) <article-title>Computational design
of proteins targeting the conserved stem region of influenza hemagglutinin</article-title>. <source>Science</source>
<volume>332</volume>, <fpage>816</fpage>–<lpage>821</lpage>.<pub-id pub-id-type="pmid">21566186</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Whitehead</surname><given-names>T. A.</given-names></name>; <name><surname>Chevalier</surname><given-names>A.</given-names></name>; <name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Dreyfus</surname><given-names>C.</given-names></name>; <name><surname>Fleishman</surname><given-names>S. J.</given-names></name>; <name><surname>De Mattos</surname><given-names>C.</given-names></name>; <name><surname>Myers</surname><given-names>C. A.</given-names></name>; <name><surname>Kamisetty</surname><given-names>H.</given-names></name>; <name><surname>Blair</surname><given-names>P.</given-names></name>; <name><surname>Wilson</surname><given-names>I. A.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2012</year>) <article-title>Optimization of affinity,
specificity, and function of designed influenza inhibitors using deep
sequencing</article-title>. <source>Nat. Biotechnol.</source>
<volume>30</volume>, <fpage>543</fpage>–<lpage>548</lpage>.<pub-id pub-id-type="pmid">22634563</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Jiang</surname><given-names>L.</given-names></name>; <name><surname>Althoff</surname><given-names>E. A.</given-names></name>; <name><surname>Clemente</surname><given-names>F. R.</given-names></name>; <name><surname>Doyle</surname><given-names>L.</given-names></name>; <name><surname>Rothlisberger</surname><given-names>D.</given-names></name>; <name><surname>Zanghellini</surname><given-names>A.</given-names></name>; <name><surname>Gallaher</surname><given-names>J. L.</given-names></name>; <name><surname>Betker</surname><given-names>J. L.</given-names></name>; <name><surname>Tanaka</surname><given-names>F.</given-names></name>; <name><surname>Barbas</surname><given-names>I.</given-names></name>; <name><surname>Carlos</surname><given-names>F.</given-names></name>; <name><surname>Hilvert</surname><given-names>D.</given-names></name>; <name><surname>Houk</surname><given-names>K. N.</given-names></name>; <name><surname>Stoddard</surname><given-names>B. L.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2008</year>) <article-title><italic>De novo</italic> computational
design of retro-aldol enzymes</article-title>. <source>Science</source>
<volume>319</volume>, <fpage>1387</fpage>–<lpage>1391</lpage>.<pub-id pub-id-type="pmid">18323453</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Richter</surname><given-names>F.</given-names></name>; et al. (<year>2012</year>) <article-title>Computational design
of catalytic dyads and oxyanion holes for ester
hydrolysis</article-title>. <source>J. Am. Chem. Soc.</source><volume>134</volume>, <fpage>16197</fpage>–<lpage>16206</lpage>.<pub-id pub-id-type="pmid">22871159</pub-id></mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Althoff</surname><given-names>E. A.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Jiang</surname><given-names>L.</given-names></name>; <name><surname>Giger</surname><given-names>L.</given-names></name>; <name><surname>Lassila</surname><given-names>J. K.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Smith</surname><given-names>M.</given-names></name>; <name><surname>Hari</surname><given-names>S.</given-names></name>; <name><surname>Kast</surname><given-names>P.</given-names></name>; <name><surname>Herschlag</surname><given-names>D.</given-names></name>; <name><surname>Hilvert</surname><given-names>D.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2012</year>) <article-title>Robust design and optimization
of retroaldol enzymes</article-title>. <source>Protein Sci.</source>
<volume>21</volume>, <fpage>717</fpage>–<lpage>726</lpage>.<pub-id pub-id-type="pmid">22407837</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Siegel</surname><given-names>J. B.</given-names></name>; <name><surname>Zanghellini</surname><given-names>A.</given-names></name>; <name><surname>Lovick</surname><given-names>H. M.</given-names></name>; <name><surname>Kiss</surname><given-names>G.</given-names></name>; <name><surname>Lambert</surname><given-names>A. R.</given-names></name>; <name><surname>St.Clair</surname><given-names>J. L.</given-names></name>; <name><surname>Gallaher</surname><given-names>J. L.</given-names></name>; <name><surname>Hilvert</surname><given-names>D.</given-names></name>; <name><surname>Gelb</surname><given-names>M. H.</given-names></name>; <name><surname>Stoddard</surname><given-names>B. L.</given-names></name>; <name><surname>Houk</surname><given-names>K. N.</given-names></name>; <name><surname>Michael</surname><given-names>F. E.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2010</year>) <article-title>Computational
design of an enzyme catalyst for a stereoselective bimolecular Diels–Alder
reaction</article-title>. <source>Science</source>
<volume>329</volume>, <fpage>309</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">20647463</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Rothlisberger</surname><given-names>D.</given-names></name>; <name><surname>Khersonsky</surname><given-names>O.</given-names></name>; <name><surname>Wollacott</surname><given-names>A. M.</given-names></name>; <name><surname>Jiang</surname><given-names>L.</given-names></name>; <name><surname>DeChancie</surname><given-names>J.</given-names></name>; <name><surname>Betker</surname><given-names>J.</given-names></name>; <name><surname>Gallaher</surname><given-names>J. L.</given-names></name>; <name><surname>Althoff</surname><given-names>E. A.</given-names></name>; <name><surname>Zanghellini</surname><given-names>A.</given-names></name>; <name><surname>Dym</surname><given-names>O.</given-names></name>; <name><surname>Albeck</surname><given-names>S.</given-names></name>; <name><surname>Houk</surname><given-names>K. N.</given-names></name>; <name><surname>Tawfik</surname><given-names>D. S.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2008</year>) <article-title>Kemp elimination
catalysts by computational enzyme design</article-title>. <source>Nature</source>
<volume>453</volume>, <fpage>190</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">18354394</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Eiben</surname><given-names>C. B.</given-names></name>; <name><surname>Siegel</surname><given-names>J. B.</given-names></name>; <name><surname>Bale</surname><given-names>J. B.</given-names></name>; <name><surname>Cooper</surname><given-names>S.</given-names></name>; <name><surname>Khatib</surname><given-names>F.</given-names></name>; <name><surname>Shen</surname><given-names>B. W.</given-names></name>; <name><surname>Players</surname><given-names>F.</given-names></name>; <name><surname>Stoddard</surname><given-names>B. L.</given-names></name>; <name><surname>Popovic</surname><given-names>Z.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name> (<year>2012</year>) <article-title>Increased Diels-Alderase
activity through backbone remodeling guided
by Foldit players</article-title>. <source>Nat. Biotechnol.</source>
<volume>30</volume>, <fpage>190</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">22267011</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Saraf</surname><given-names>M. C.</given-names></name>; <name><surname>Moore</surname><given-names>G. L.</given-names></name>; <name><surname>Goodey</surname><given-names>N. M.</given-names></name>; <name><surname>Cao</surname><given-names>V. Y.</given-names></name>; <name><surname>Benkovic</surname><given-names>S. J.</given-names></name>; <name><surname>Maranas</surname><given-names>C. D.</given-names></name> (<year>2006</year>) <article-title>IPRO: an iterative
computational protein library redesign
and optimization procedure</article-title>. <source>Biophys. J.</source>
<volume>90</volume>, <fpage>4167</fpage>–<lpage>4180</lpage>.<pub-id pub-id-type="pmid">16513775</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Khoury</surname><given-names>G. A.</given-names></name>; <name><surname>Fazelinia</surname><given-names>H.</given-names></name>; <name><surname>Chin</surname><given-names>J. W.</given-names></name>; <name><surname>Pantazes</surname><given-names>R. J.</given-names></name>; <name><surname>Cirino</surname><given-names>P. C.</given-names></name>; <name><surname>Maranas</surname><given-names>C. D.</given-names></name> (<year>2009</year>) <article-title>Computational
design of <italic>Candida boidinii </italic>xylose reductase for altered
cofactor specificity</article-title>. <source>Protein Sci.</source>
<volume>18</volume>, <fpage>2125</fpage>–<lpage>2138</lpage>.<pub-id pub-id-type="pmid">19693930</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Renfrew</surname><given-names>P. D.</given-names></name>; <name><surname>Choi</surname><given-names>E. J.</given-names></name>; <name><surname>Bonneau</surname><given-names>R.</given-names></name>; <name><surname>Kuhlman</surname><given-names>B.</given-names></name> (<year>2012</year>) <article-title>Incorporation of noncanonical
amino acids into Rosetta and use in computational protein–peptide
interface design</article-title>. <source>PLoS One</source>
<volume>7</volume>, <fpage>e32637</fpage>.<pub-id pub-id-type="pmid">22431978</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Petrov</surname><given-names>D.</given-names></name>; <name><surname>Margreitter</surname><given-names>C.</given-names></name>; <name><surname>Grandits</surname><given-names>M.</given-names></name>; <name><surname>Oostenbrink</surname><given-names>C.</given-names></name>; <name><surname>Zagrovic</surname><given-names>B.</given-names></name> (<year>2013</year>) <article-title>A systematic framework for molecular dynamics simulations
of protein post-translational modifications</article-title>. <source>PLoS Comput. Biol.</source>
<volume>9</volume>, <fpage>e1003154</fpage>.<pub-id pub-id-type="pmid">23874192</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Margreitter</surname><given-names>C.</given-names></name>; <name><surname>Petrov</surname><given-names>D.</given-names></name>; <name><surname>Zagrovic</surname><given-names>B.</given-names></name> (<year>2013</year>) <article-title>Vienna-PTM web server: A toolkit
for MD simulations of protein post-translational modifications</article-title>. <source>Nucleic Acids Res.</source>
<volume>41</volume>, <fpage>W422</fpage>–<lpage>W426</lpage>.<pub-id pub-id-type="pmid">23703210</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Klepeis</surname><given-names>J. L.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Tsokos</surname><given-names>C. G.</given-names></name>; <name><surname>Argyropoulos</surname><given-names>E.</given-names></name>; <name><surname>Spruce</surname><given-names>L.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2003</year>) <article-title>Integrated computational and experimental
approach for lead optimization and design of compstatin variants with
improved activity</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>125</volume>, <fpage>8422</fpage>–<lpage>8423</lpage>.<pub-id pub-id-type="pmid">12848533</pub-id></mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Klepeis</surname><given-names>J. L.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Tsokos</surname><given-names>C. G.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2004</year>) <article-title>Design
of peptide analogues with improved activity using a novel <italic>de novo</italic> protein design approach</article-title>. <source>Ind.
Eng. Chem. Res.</source>
<volume>43</volume>, <fpage>3817</fpage>–<lpage>3826</lpage>.</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Bellows</surname><given-names>M. L.</given-names></name>; <name><surname>Taylor</surname><given-names>M. S.</given-names></name>; <name><surname>Cole</surname><given-names>P. A.</given-names></name>; <name><surname>Shen</surname><given-names>L.</given-names></name>; <name><surname>Siliciano</surname><given-names>R. F.</given-names></name>; <name><surname>Fung</surname><given-names>H. K.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2010</year>) <article-title>Discovery of entry inhibitors for
HIV-1 via a new <italic>de novo</italic> protein design framework</article-title>. <source>Biophys. J.</source>
<volume>99</volume>, <fpage>3445</fpage>–<lpage>3453</lpage>.<pub-id pub-id-type="pmid">21081094</pub-id></mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Bellows</surname><given-names>M. L.</given-names></name>; <name><surname>Fung</surname><given-names>H. K.</given-names></name>; <name><surname>Taylor</surname><given-names>M. S.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Lopez
de Victoria</surname><given-names>A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name> (<year>2010</year>) <article-title>New compstatin variants through two <italic>de novo</italic> protein design frameworks</article-title>. <source>Biophys. J.</source>
<volume>98</volume>, <fpage>2337</fpage>–<lpage>2346</lpage>.<pub-id pub-id-type="pmid">20483343</pub-id></mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Fung</surname><given-names>H. K.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Taylor</surname><given-names>M. S.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name> (<year>2008</year>) <article-title>Toward full-sequence <italic>de novo</italic> protein design with flexible templates for human
β-defensin-2</article-title>. <source>Biophys. J.</source>
<volume>94</volume>, <fpage>584</fpage>–<lpage>599</lpage>.<pub-id pub-id-type="pmid">17827237</pub-id></mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Bellows-Peterson</surname><given-names>M. L.</given-names></name>; <name><surname>Fung</surname><given-names>H. K.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Kieslich</surname><given-names>C. A.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Wareham</surname><given-names>K. J.</given-names></name>; <name><surname>Monk</surname><given-names>P. N.</given-names></name>; <name><surname>Hawksworth</surname><given-names>O. A.</given-names></name>; <name><surname>Woodruff</surname><given-names>T. M.</given-names></name> (<year>2012</year>) <article-title><italic>De novo</italic> peptide design with C3a receptor
agonist and antagonist activities: Theoretical predictions and experimental
validation</article-title>. <source>J. Med. Chem.</source>
<volume>55</volume>, <fpage>4159</fpage>–<lpage>4168</lpage>.<pub-id pub-id-type="pmid">22500977</pub-id></mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="journal" id="cit46"><name><surname>Smadbeck</surname><given-names>J.</given-names></name>; <name><surname>Peterson</surname><given-names>M. B.</given-names></name>; <name><surname>Khoury</surname><given-names>G. A.</given-names></name>; <name><surname>Taylor</surname><given-names>M. S.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2013</year>) <article-title>Protein
WISDOM: A workbench for in silico <italic>de novo</italic> design
of biomolecules</article-title>. <source>J. Visualized Exp.</source>
<fpage>e50476</fpage>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="journal" id="cit47"><name><surname>Lopez
de Victoria</surname><given-names>A.</given-names></name>; <name><surname>Gorham</surname><given-names>R. D.</given-names></name>; <name><surname>Bellows-Peterson</surname><given-names>M. L.</given-names></name>; <name><surname>Ling</surname><given-names>J.</given-names></name>; <name><surname>Lo</surname><given-names>D. D.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name> (<year>2011</year>) <article-title>A new generation
of potent complement inhibitors of the compstatin family</article-title>. <source>Chem. Biol. Drug Des.</source>
<volume>77</volume>, <fpage>431</fpage>–<lpage>440</lpage>.<pub-id pub-id-type="pmid">21352502</pub-id></mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Bellows</surname><given-names>M. L.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2010</year>) <article-title>Computational methods for <italic>de novo</italic> protein
design and its applications to the human immunodeficiency virus 1,
purine nucleoside phosphorylase, ubiquitin specific protease 7, and
histone demethylases</article-title>. <source>Curr. Drug Targets</source>
<volume>11</volume>, <fpage>264</fpage>–<lpage>278</lpage>.<pub-id pub-id-type="pmid">20210752</pub-id></mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Tamamis</surname><given-names>P.</given-names></name>; <name><surname>López de Victoria</surname><given-names>A.</given-names></name>; <name><surname>Gorham</surname><given-names>R. D.</given-names></name>; <name><surname>Bellows-Peterson</surname><given-names>M. L.</given-names></name>; <name><surname>Pierou</surname><given-names>P.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Archontis</surname><given-names>G.</given-names></name> (<year>2012</year>) <article-title>Molecular
dynamics in drug design: New generations of compstatin analogs</article-title>. <source>Chem. Biol. Drug Des.</source>
<volume>79</volume>, <fpage>703</fpage>–<lpage>718</lpage>.<pub-id pub-id-type="pmid">22233517</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <mixed-citation publication-type="journal" id="cit50"><name><surname>Khoury</surname><given-names>G. A.</given-names></name>; <name><surname>Thompson</surname><given-names>J. P.</given-names></name>; <name><surname>Smadbeck</surname><given-names>J.</given-names></name>; <name><surname>Kieslich</surname><given-names>C. A.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name> (<year>2013</year>) <article-title>Forcefield_PTM: <italic>Ab initio</italic> charge and AMBER forcefield parameters for frequently
occurring post-translational modifications</article-title>. <source>J. Chem. Theory Comput.</source>
<volume>9</volume>, <fpage>5653</fpage>–<lpage>5674</lpage>.<pub-id pub-id-type="pmid">24489522</pub-id></mixed-citation>
    </ref>
    <ref id="ref51">
      <mixed-citation publication-type="journal" id="cit51"><name><surname>Duan</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Chowdhury</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>M. C.</given-names></name>; <name><surname>Xiong</surname><given-names>G.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Yang</surname><given-names>R.</given-names></name>; <name><surname>Cieplak</surname><given-names>P.</given-names></name>; <name><surname>Luo</surname><given-names>R.</given-names></name>; <name><surname>Lee</surname><given-names>T.</given-names></name>; <name><surname>Caldwell</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Kollman</surname><given-names>P.</given-names></name> (<year>2003</year>) <article-title>A point-charge force
field for molecular mechanics simulations of proteins based on condensed-phase
quantum mechanical calculations</article-title>. <source>J. Comput.
Chem.</source>
<volume>24</volume>, <fpage>1999</fpage>–<lpage>2012</lpage>.<pub-id pub-id-type="pmid">14531054</pub-id></mixed-citation>
    </ref>
    <ref id="ref52">
      <mixed-citation publication-type="journal" id="cit52"><name><surname>Magotti</surname><given-names>P.</given-names></name>; <name><surname>Ricklin</surname><given-names>D.</given-names></name>; <name><surname>Qu</surname><given-names>H.</given-names></name>; <name><surname>Wu</surname><given-names>Y.-Q.</given-names></name>; <name><surname>Kaznessis</surname><given-names>Y. N.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2009</year>) <article-title>Structure–kinetic
relationship analysis of the
therapeutic complement inhibitor compstatin</article-title>. <source>J. Mol. Recognit.</source>
<volume>22</volume>, <fpage>495</fpage>–<lpage>505</lpage>.<pub-id pub-id-type="pmid">19658192</pub-id></mixed-citation>
    </ref>
    <ref id="ref53">
      <mixed-citation publication-type="journal" id="cit53"><name><surname>Gorham</surname><given-names>R. D.</given-names><suffix>Jr</suffix></name>; <name><surname>Forest</surname><given-names>D. L.</given-names></name>; <name><surname>Tamamis</surname><given-names>P.</given-names></name>; <name><surname>López
de Victoria</surname><given-names>A.</given-names></name>; <name><surname>Kraszni</surname><given-names>M.</given-names></name>; <name><surname>Kieslich</surname><given-names>C. A.</given-names></name>; <name><surname>Banna</surname><given-names>C. D.</given-names></name>; <name><surname>Bellows-Peterson</surname><given-names>M. L.</given-names></name>; <name><surname>Larive</surname><given-names>C. K.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Archontis</surname><given-names>G.</given-names></name>; <name><surname>Johnson</surname><given-names>L. V.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name> (<year>2013</year>) <article-title>Novel compstatin family peptides
inhibit complement activation by drusen-like deposits in human retinal
pigmented epithelial cell cultures</article-title>. <source>Exp. Eye
Res.</source>
<volume>116C</volume>, <fpage>96</fpage>–<lpage>108</lpage>.<pub-id pub-id-type="pmid">23954241</pub-id></mixed-citation>
    </ref>
    <ref id="ref54">
      <mixed-citation publication-type="journal" id="cit54"><name><surname>Brooks</surname><given-names>B.
R.</given-names></name>; et al. (<year>2009</year>) <article-title>CHARMM:
The biomolecular simulation program</article-title>. <source>J. Comput.
Chem.</source><volume>30</volume>, <fpage>1545</fpage>–<lpage>1614</lpage>.<pub-id pub-id-type="pmid">19444816</pub-id></mixed-citation>
    </ref>
    <ref id="ref55">
      <mixed-citation publication-type="journal" id="cit55"><name><surname>Janssen</surname><given-names>B.
J. C.</given-names></name>; <name><surname>Halff</surname><given-names>E. F.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name>; <name><surname>Gros</surname><given-names>P.</given-names></name> (<year>2007</year>) <article-title>Structure of compstatin
in complex with complement component C3c reveals a new mechanism of
complement inhibition</article-title>. <source>J. Biol. Chem.</source>
<volume>282</volume>, <fpage>29241</fpage>–<lpage>29247</lpage>.<pub-id pub-id-type="pmid">17684013</pub-id></mixed-citation>
    </ref>
    <ref id="ref56">
      <mixed-citation publication-type="journal" id="cit56"><name><surname>Tamamis</surname><given-names>P.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Archontis</surname><given-names>G.</given-names></name> (<year>2010</year>) <article-title>Species specificity
of the complement inhibitor compstatin investigated by all-atom molecular
dynamics simulations</article-title>. <source>Proteins: Struct., Funct.,
Bioinf.</source>
<volume>78</volume>, <fpage>2655</fpage>–<lpage>2667</lpage>.</mixed-citation>
    </ref>
    <ref id="ref57">
      <mixed-citation publication-type="journal" id="cit57"><name><surname>Tamamis</surname><given-names>P.</given-names></name>; <name><surname>Pierou</surname><given-names>P.</given-names></name>; <name><surname>Mytidou</surname><given-names>C.</given-names></name>; <name><surname>Floudas</surname><given-names>C. A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Archontis</surname><given-names>G.</given-names></name> (<year>2011</year>) <article-title>Design of
a modified mouse protein with ligand binding
properties of its human analog by molecular dynamics simulations:
The case of C3 inhibition by compstatin</article-title>. <source>Proteins:
Struct., Funct., Bioinf.</source>
<volume>79</volume>, <fpage>3166</fpage>–<lpage>3179</lpage>.</mixed-citation>
    </ref>
    <ref id="ref58">
      <mixed-citation publication-type="journal" id="cit58"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Skolnick</surname><given-names>J.</given-names></name> (<year>2005</year>) <article-title>TM-align: A protein structure alignment algorithm based
on the TM-score</article-title>. <source>Nucleic Acids Res.</source>
<volume>33</volume>, <fpage>2302</fpage>–<lpage>2309</lpage>.<pub-id pub-id-type="pmid">15849316</pub-id></mixed-citation>
    </ref>
    <ref id="ref59">
      <mixed-citation publication-type="book" id="cit59"><source>MarvinSketch</source>, version 6.0.3; (<year>2010</year>) <publisher-name>ChemAxon</publisher-name>, <publisher-loc>Budapest,
Hungary</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref60">
      <mixed-citation publication-type="book" id="cit60"><source>TINKER</source>, version 5.0;
(<year>2010</year>) <publisher-name>Washington University</publisher-name>, <publisher-loc>St. Louis,
MO</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref61">
      <mixed-citation publication-type="journal" id="cit61"><name><surname>Cornell</surname><given-names>W.
D.</given-names></name>; <name><surname>Cieplak</surname><given-names>P.</given-names></name>; <name><surname>Bayly</surname><given-names>C. I.</given-names></name>; <name><surname>Gould</surname><given-names>I. R.</given-names></name>; <name><surname>Merz</surname><given-names>K. M.</given-names></name>; <name><surname>Ferguson</surname><given-names>D. M.</given-names></name>; <name><surname>Spellmeyer</surname><given-names>D. C.</given-names></name>; <name><surname>Fox</surname><given-names>T.</given-names></name>; <name><surname>Caldwell</surname><given-names>J. W.</given-names></name>; <name><surname>Kollman</surname><given-names>P. A.</given-names></name> (<year>1995</year>) <article-title>A second
generation force field for the simulation
of proteins, nucleic acids, and organic molecules</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>117</volume>, <fpage>5179</fpage>–<lpage>5197</lpage>.</mixed-citation>
    </ref>
    <ref id="ref62">
      <mixed-citation publication-type="computer-program" id="cit62"><person-group person-group-type="allauthors"><name><surname>Frisch</surname><given-names>M. J.</given-names></name></person-group><etal/> (<year>2004</year>) <source>Gaussian 03</source>, Revision C.02; <publisher-name>Gaussian
Inc.</publisher-name>, <publisher-loc>Wallingford, CT</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref63">
      <mixed-citation publication-type="journal" id="cit63"><name><surname>Lee</surname><given-names>C.</given-names></name>; <name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Parr</surname><given-names>R. G.</given-names></name> (<year>1988</year>) <article-title>Development
of the Colle–Salvetti
correlation-energy formula into a functional of the electron density</article-title>. <source>Phys. Rev. B</source>
<volume>37</volume>, <fpage>785</fpage>.</mixed-citation>
    </ref>
    <ref id="ref64">
      <mixed-citation publication-type="journal" id="cit64"><name><surname>Miehlich</surname><given-names>B.</given-names></name>; <name><surname>Savin</surname><given-names>A.</given-names></name>; <name><surname>Stoll</surname><given-names>H.</given-names></name>; <name><surname>Preuss</surname><given-names>H.</given-names></name> (<year>1989</year>) <article-title>Results obtained with
the correlation energy density functionals of Becke and Lee, Yang,
and Parr</article-title>. <source>Chem. Phys. Lett.</source>
<volume>157</volume>, <fpage>200</fpage>–<lpage>206</lpage>.</mixed-citation>
    </ref>
    <ref id="ref65">
      <mixed-citation publication-type="journal" id="cit65"><name><surname>Becke</surname><given-names>A. D.</given-names></name> (<year>1993</year>) <article-title>Density-functional
thermochemistry. III. The role of exact exchange</article-title>. <source>J. Chem. Phys.</source>
<volume>98</volume>, <fpage>5648</fpage>–<lpage>5652</lpage>.</mixed-citation>
    </ref>
    <ref id="ref66">
      <mixed-citation publication-type="journal" id="cit66"><name><surname>Kendall</surname><given-names>R. A.</given-names></name>; <name><surname>Thom H. Dunning</surname><given-names>J.</given-names></name>; <name><surname>Harrison</surname><given-names>R. J.</given-names></name> (<year>1992</year>) <article-title>Electron affinities of the first-row
atoms revisited. Systematic basis sets and wave functions</article-title>. <source>J. Chem. Phys.</source>
<volume>96</volume>, <fpage>6796</fpage>–<lpage>6806</lpage>.</mixed-citation>
    </ref>
    <ref id="ref67">
      <mixed-citation publication-type="journal" id="cit67"><name><surname>Mennucci</surname><given-names>B.</given-names></name>; <name><surname>Cammi</surname><given-names>R.</given-names></name>; <name><surname>Tomasi</surname><given-names>J.</given-names></name> (<year>1999</year>) <article-title>Analytical free energy second derivatives
with respect to nuclear coordinates: Complete formulation for electrostatic
continuum solvation models</article-title>. <source>J. Chem. Phys.</source>
<volume>110</volume>, <fpage>6858</fpage>–<lpage>6870</lpage>.</mixed-citation>
    </ref>
    <ref id="ref68">
      <mixed-citation publication-type="journal" id="cit68"><name><surname>Tomasi</surname><given-names>J.</given-names></name>; <name><surname>Mennucci</surname><given-names>B.</given-names></name>; <name><surname>Cances</surname><given-names>E.</given-names></name> (<year>1999</year>) <article-title>The IEF version
of the PCM solvation
method: An overview of a new method addressed to study molecular solutes
at the QM <italic>ab initio</italic> level</article-title>. <source>J. Mol. Struct.: THEOCHEM</source>
<volume>464</volume>, <fpage>211</fpage>–<lpage>226</lpage>.</mixed-citation>
    </ref>
    <ref id="ref69">
      <mixed-citation publication-type="journal" id="cit69"><name><surname>Richards</surname><given-names>F. M.</given-names></name> (<year>1977</year>) <article-title>Areas,
Volumes, Packing, and Protein Structure</article-title>. <source>Annu.
Rev. Biophys. Bioeng.</source>
<volume>6</volume>, <fpage>151</fpage>–<lpage>176</lpage>.<pub-id pub-id-type="pmid">326146</pub-id></mixed-citation>
    </ref>
    <ref id="ref70">
      <mixed-citation publication-type="journal" id="cit70"><name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Kollman</surname><given-names>P. A.</given-names></name>; <name><surname>Case</surname><given-names>D. A.</given-names></name> (<year>2006</year>) <article-title>Automatic atom type
and bond type perception in molecular mechanical calculations</article-title>. <source>J. Mol. Graph. Model.</source>
<volume>25</volume>, <fpage>247</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">16458552</pub-id></mixed-citation>
    </ref>
    <ref id="ref71">
      <mixed-citation publication-type="journal" id="cit71"><name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Wolf</surname><given-names>R. M.</given-names></name>; <name><surname>Caldwell</surname><given-names>J. W.</given-names></name>; <name><surname>Kollman</surname><given-names>P. A.</given-names></name>; <name><surname>Case</surname><given-names>D. A.</given-names></name> (<year>2004</year>) <article-title>Development
and testing of a general Amber force field</article-title>. <source>J. Comput. Chem.</source>
<volume>25</volume>, <fpage>1157</fpage>–<lpage>1174</lpage>.<pub-id pub-id-type="pmid">15116359</pub-id></mixed-citation>
    </ref>
    <ref id="ref72">
      <mixed-citation publication-type="book" id="cit72"><person-group person-group-type="allauthors"><name><surname>Janeway</surname><given-names>C. A.</given-names></name>, <name><surname>Travers</surname><given-names>P.</given-names></name>, <name><surname>Walport</surname><given-names>M.</given-names></name>, and <name><surname>Shlomchik</surname><given-names>M. J.</given-names></name></person-group> (<year>2001</year>) <source>Immunobiology</source>; <publisher-name>Garland Science</publisher-name>, <publisher-loc>New York</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref73">
      <mixed-citation publication-type="journal" id="cit73"><name><surname>Sahu</surname><given-names>A.</given-names></name>; <name><surname>Morikis</surname><given-names>D.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2003</year>) <article-title>Compstatin, a peptide inhibitor of
complement, exhibits species-specific binding to complement component
C3</article-title>. <source>Mol. Immunol.</source>
<volume>39</volume>, <fpage>557</fpage>–<lpage>566</lpage>.<pub-id pub-id-type="pmid">12431389</pub-id></mixed-citation>
    </ref>
    <ref id="ref74">
      <mixed-citation publication-type="journal" id="cit74"><name><surname>Kovacs</surname><given-names>G. G.</given-names></name>; <name><surname>Gasque</surname><given-names>P.</given-names></name>; <name><surname>Ströbel</surname><given-names>T.</given-names></name>; <name><surname>Lindeck-Pozza</surname><given-names>E.</given-names></name>; <name><surname>Strohschneider</surname><given-names>M.</given-names></name>; <name><surname>Ironside</surname><given-names>J. W.</given-names></name>; <name><surname>Budka</surname><given-names>H.</given-names></name>; <name><surname>Guentchev</surname><given-names>M.</given-names></name> (<year>2004</year>) <article-title>Complement
activation in human prion disease</article-title>. <source>Neurobiol.
Dis.</source>
<volume>15</volume>, <fpage>21</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">14751767</pub-id></mixed-citation>
    </ref>
    <ref id="ref75">
      <mixed-citation publication-type="journal" id="cit75"><name><surname>Java</surname><given-names>A.</given-names></name>; <name><surname>Atkinson</surname><given-names>J.</given-names></name>; <name><surname>Salmon</surname><given-names>J.</given-names></name> (<year>2013</year>) <article-title>Defective
complement inhibitory function
predisposes to renal disease</article-title>. <source>Annu. Rev. Med.</source>
<volume>64</volume>, <fpage>307</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">23121180</pub-id></mixed-citation>
    </ref>
    <ref id="ref76">
      <mixed-citation publication-type="journal" id="cit76"><name><surname>Ricklin</surname><given-names>D.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2013</year>) <article-title>Complement in immune
and inflammatory disorders: Therapeutic
interventions</article-title>. <source>J. Immunol.</source>
<volume>190</volume>, <fpage>3839</fpage>–<lpage>3847</lpage>.<pub-id pub-id-type="pmid">23564578</pub-id></mixed-citation>
    </ref>
    <ref id="ref77">
      <mixed-citation publication-type="journal" id="cit77"><name><surname>Rensen</surname><given-names>S. S.</given-names></name>; <name><surname>Slaats</surname><given-names>Y.</given-names></name>; <name><surname>Driessen</surname><given-names>A.</given-names></name>; <name><surname>Peutz-Kootstra</surname><given-names>C. J.</given-names></name>; <name><surname>Nijhuis</surname><given-names>J.</given-names></name>; <name><surname>Steffensen</surname><given-names>R.</given-names></name>; <name><surname>Greve</surname><given-names>J. W.</given-names></name>; <name><surname>Buurman</surname><given-names>W. A.</given-names></name> (<year>2009</year>) <article-title>Activation
of the complement system in human nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source>
<volume>50</volume>, <fpage>1809</fpage>–<lpage>1817</lpage>.<pub-id pub-id-type="pmid">19821522</pub-id></mixed-citation>
    </ref>
    <ref id="ref78">
      <mixed-citation publication-type="book" id="cit78"><source>PyMOL</source>,
version 1.3; <publisher-name>Delano Scientific LLC</publisher-name>, <year>2008</year>.</mixed-citation>
    </ref>
    <ref id="ref79">
      <mixed-citation publication-type="journal" id="cit79"><name><surname>Chiu</surname><given-names>T.-L.</given-names></name>; <name><surname>Mulakala</surname><given-names>C.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name>; <name><surname>Kaznessis</surname><given-names>Y. N.</given-names></name> (<year>2008</year>) <article-title>Development
of a new pharmacophore model that discriminates active compstatin
analogs</article-title>. <source>Chem. Biol. Drug Des.</source>
<volume>72</volume>, <fpage>249</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">18844671</pub-id></mixed-citation>
    </ref>
    <ref id="ref80">
      <mixed-citation publication-type="computer-program" id="cit80"><person-group person-group-type="allauthors"><name><surname>Case</surname><given-names>D. A.</given-names></name></person-group><etal/> (<year>2010</year>) <source>Amber 11</source>, <publisher-name>University
of California</publisher-name>, <publisher-loc>San Francisco</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref81">
      <mixed-citation publication-type="journal" id="cit81"><name><surname>Onufriev</surname><given-names>A.</given-names></name>; <name><surname>Bashford</surname><given-names>D.</given-names></name>; <name><surname>Case</surname><given-names>D. A.</given-names></name> (<year>2000</year>) <article-title>Modification
of the generalized Born
Model suitable for macromolecules</article-title>. <source>J. Phys.
Chem. B</source>
<volume>104</volume>, <fpage>3712</fpage>–<lpage>3720</lpage>.</mixed-citation>
    </ref>
    <ref id="ref82">
      <mixed-citation publication-type="journal" id="cit82"><name><surname>Onufriev</surname><given-names>A.</given-names></name>; <name><surname>Bashford</surname><given-names>D.</given-names></name>; <name><surname>Case</surname><given-names>D. A.</given-names></name> (<year>2004</year>) <article-title>Exploring
protein native states and
large-scale conformational changes with a modified generalized born
model</article-title>. <source>Proteins: Struct., Funct., Bioinf.</source>
<volume>55</volume>, <fpage>383</fpage>–<lpage>394</lpage>.</mixed-citation>
    </ref>
    <ref id="ref83">
      <mixed-citation publication-type="journal" id="cit83"><name><surname>Hou</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name> (<year>2011</year>) <article-title>Assessing the performance
of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free
energy calculations based on molecular dynamics simulations</article-title>. <source>J. Chem. Inf. Model.</source>
<volume>51</volume>, <fpage>69</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">21117705</pub-id></mixed-citation>
    </ref>
    <ref id="ref84">
      <mixed-citation publication-type="journal" id="cit84"><name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Sun</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name> (<year>2013</year>) <article-title>Assessing the performance
of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and
ligand charge models</article-title>. <source>J. Phys. Chem. B</source>
<volume>117</volume>, <fpage>8408</fpage>–<lpage>8421</lpage>.<pub-id pub-id-type="pmid">23789789</pub-id></mixed-citation>
    </ref>
    <ref id="ref85">
      <mixed-citation publication-type="journal" id="cit85"><name><surname>Lilien</surname><given-names>R. H.</given-names></name>; <name><surname>Stevens</surname><given-names>B. W.</given-names></name>; <name><surname>Anderson</surname><given-names>A. C.</given-names></name>; <name><surname>Donald</surname><given-names>B. R.</given-names></name> (<year>2005</year>) <article-title>A novel ensemble-based
scoring and search algorithm for protein redesign and its application
to modify the substrate specificity of the gramicidin synthetase a
phenylalanine adenylation enzyme</article-title>. <source>J. Comput.
Biol.</source>
<volume>12</volume>, <fpage>740</fpage>–<lpage>761</lpage>.<pub-id pub-id-type="pmid">16108714</pub-id></mixed-citation>
    </ref>
    <ref id="ref86">
      <mixed-citation publication-type="book" id="cit86"><person-group person-group-type="allauthors"><name><surname>Lidl</surname><given-names>R.</given-names></name>, and <name><surname>Neiderreiter</surname><given-names>H.</given-names></name></person-group> (<year>1983</year>) <article-title>Finite fields</article-title>. In <source>Encyclopedia of Mathematics
and its Applications</source>, <publisher-name>Addision-Wesley</publisher-name>, <publisher-loc>Reading, MA</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="ref87">
      <mixed-citation publication-type="journal" id="cit87"><name><surname>Miller</surname><given-names>B. R.</given-names><suffix>III</suffix></name>; <name><surname>McGee</surname><given-names>T. D.</given-names><suffix>Jr</suffix></name>; <name><surname>Swails</surname><given-names>J. M.</given-names></name>; <name><surname>Homeyer</surname><given-names>N.</given-names></name>; <name><surname>Gohlke</surname><given-names>H.</given-names></name>; <name><surname>Roitberg</surname><given-names>A. E.</given-names></name> (<year>2012</year>) <article-title>MMPBSA. py: An efficient
program for end-state free energy calculations</article-title>. <source>J. Chem. Theory Comput.</source>
<volume>8</volume>, <fpage>3314</fpage>–<lpage>3321</lpage>.</mixed-citation>
    </ref>
    <ref id="ref88">
      <mixed-citation publication-type="journal" id="cit88"><name><surname>Katragadda</surname><given-names>M.</given-names></name>; <name><surname>Magotti</surname><given-names>P.</given-names></name>; <name><surname>Sfyroera</surname><given-names>G.</given-names></name>; <name><surname>Lambris</surname><given-names>J. D.</given-names></name> (<year>2006</year>) <article-title>Hydrophobic effect
and hydrogen bonds account for the improved activity of a complement
inhibitor, compstatin</article-title>. <source>J. Med. Chem.</source>
<volume>49</volume>, <fpage>4616</fpage>–<lpage>4622</lpage>.<pub-id pub-id-type="pmid">16854067</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
